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CHAPTER 1 
Introduction 
 
I. Physiological and immune functions of the lung 
The lung is an internal organ that is constantly exposed to the external environment. It is 
also frequently targeted by infectious pathogens. The physiologic function of the lungs are 
critical for good health and collateral tissue damage is detrimental, which presents an 
immunologic dilemma for the host. While one of the most crucial functions of the lung is to 
serve as the organ of gas exchange, it also has a major role in mediating host defense (1).  
Breathing (ventilation) is the physiologic aspect of respiration, the means of gas 
exchange in lungs. Carbon dioxide exchange (CO2) is produced during the oxidation of food 
molecules and is exchanged for oxygen (O2) found in outside air. Fresh air is moved into and out 
of the airways through the trachea and into the bronchi by convection of the air. Bronchioles 
terminate into alveoli, where subsequent movement of gases between alveoli and blood in 
pulmonary capillaries are mediated by the random movement of O2 and CO2 molecules from 
regions of high to low concentrations (2). The pulmonary interstitium contains elastic and 
collagen fibers that confer the elasticity and structural integrity of lung tissues, and is rich in 
fibroblasts. The interstitium separates the endothelium and epithelium of pulmonary tissue. The 
pulmonary interstitium is a supportive structure composed of a thin layer of cells found between 
alveoli. Growth of this fibrous tissue is responsible for pulmonary fibrosis that results in patients 
experiencing breathing difficulty. A schematic of mammalian lung anatomy can be found in 
Figure 1.1.  
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The lung is an organ that can be divided into two major anatomical compartments: the 
bronchoalveolar space, clinically and experimentally accessible by lavage, and all else 
encompassed in the lung tissue (3). Under homeostatic conditions, alveolar macrophages account 
for up to 95% of all leukocytes in the lungs bronchoalveolar air spaces, vastly out numbering 
lymphocytes (1-4%) and neutrophils (~1%) (4).   
The lung epithelium, including mucus and ciliated epithelial cells that line the bronchi 
and bronchioles, serves as a physical barrier to protect from environmental insults such as 
infectious agents and harmful particulate matter (5). Mucus traps potentially damaging particles 
and transports them by action of the mucociliary escalator that covers the nose, bronchi, and 
bronchioles. Antimicrobial surfactant proteins are able to opsonize bacteria. Respiratory 
epithelium is capable of directly sensing pathogens and even releasing cytokines such as 
interleukin-25 (IL-25), IL-33, and thymic stromal lymphopoietin (TSLP). These innate processes 
inherent to the lung parenchyma are generally able to maintain the semi-sterility of the lungs 
without the intervention of the conventional immune system. 
The largest population of lung leukocytes at stead state are alveolar macrophages (6), 
which are the major orchestrators of pulmonary immune and inflammatory responses. These 
tissue-resident macrophages, also known as dust cells in reference to their function, are located 
in alveolar spaces and are highly active given their position at an important boundary between 
inside the body and the outside environment (7). Their role in the non-infected host is to repress 
the induction of immune responses. Resident alveolar macrophages are constantly encountering 
inhaled material due to their anatomical position; thus, it is critical to the health of the host that 
these cells are kept in a relatively quiescent state and have an anti-inflammatory phenotype to 
prevent collateral damage to the lung parenchyma in response to innocuous antigens and 
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maintain homeostasis (7). This is apparent by the downregulation of the phagocytic cell 
membrane receptor CD11b (8), which is a canonical surface marker on most macrophage subsets 
typically used to identify macrophages. Instead, alveolar macrophages are identified 
phenotypically by their co-expression of F4/80 and CD11c (9). 
 Neutrophils play an indispensable role in the innate immune response to lung infection as 
they are the first cells recruited in injured tissues (10). Intriguingly, the lungs appear to play an 
immunoprotective role by physical sequestration of activated neutrophils during inflammatory 
conditions by filtering primed neutrophils from circulation and being a site for de-priming (11). 
Whether this phenomenon is active or passive remains unknown. Regardless, it is interesting that 
activated inflammatory cells would enter the lung for deactivation, highlighting the potent anti-
inflammatory force of the lung microenvironment. 
Dysfunction of immunological processes in the lung results in injury to this organ, which 
can be detrimental to the host’s viability and quality of life.  
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Figure 1.1. Diagram of lung anatomy and cross-sections of bronchi, bronchioles, alveolar 
ducts, and alveoli. A) Gross anatomy of the lung and thorax. B) Bronchial wall. C) Terminal 
airway and alveoli. D) Alveolar structure. Richard M. Effros, Anatomy, development, and 
physiology of the lungs. GI Motility online (2006).  
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II. Radiation-induced lung injury 
A. Adverse effects of radiation therapy for lung cancer. Radiation therapy is defined as the 
medical use of ionizing radiation to kill malignant cells and control tumor growth. It has become 
the most important nonsurgical modality for the treatment of cancer, with nearly 1 million people 
of the approximately 1.4 million who developed cancer receiving treatment with radiation in the 
United States (American Society for Therapeutic Radiation Oncology). Radiation therapy is 
advantageous over surgery, being that it is non-invasive and potentially organ preserving. 
Additionally, radiation therapy is tremendously cost effective, as it only accounts for 5% of the 
total cost of cancer care (12). 
Radiation therapy utilizes ionizing radiation, which causes mitotic cell death followed by 
tissue repair and remodeling (13). The severity of tissue damage depends on several factors, 
including radiation dose, quality, fractionation, tissue radiosensitivity, and the repair and 
repopulation capacity of the organ (14). The degree of radiosensitivity of an organ refers to its 
relative susceptibility to ionizing radiation (15). The radiosensitivity of a tissue is directly 
correlated to the proliferative potential of its constituent cells and inversely proportional to the 
degree of their differentiation. Due to the lack of regenerative capacity, the lung is one of the 
most radiosensitive normal tissues in the body (16). The high radiosensitivity of the lung 
parenchyma is the major dose-limiting factor in thoracic radiation therapy. 
The therapeutic ratio of radiation therapy refers to the balance between the probability of 
tumor control or cure and the risk of normal tissue complications. The probability of curing a 
tumor increases with increasing radiation dose (17). However, it is an unavoidable consequence 
that normal tissue will be included in the radiation field. Thus, a fundamental and ongoing 
problem of radiation therapy is that the desired anti-tumor effect is coupled with injury to 
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surrounding, otherwise normal and healthy tissues (Figure 1.2). One promising strategy to 
improve the therapeutic ratio of radiation therapy is to administer it in combination with a 
radiation protector or mitigator, (see Chapter 1, Section IIE for current treatments of RILI). 
Radiation-induced lung injury (RILI) to normal tissue is a major concern in non-small 
cell lung cancer (NSCLC). Radiotherapy given concurrently with chemotherapy is the 
conventional treatment for locally advanced NSCLC presenting as unresectable, stage III disease 
in approximately 50,000 Americans per year. There is an associated overall 5-year survival rate 
of 20%, emphasizing the need to improve the efficacy of concurrent chemo-radiotherapy (18, 
19). High intensity radiotherapy could be more effective but the therapeutic ratio is limited by 
lung tissue toxicity.  
RILI was first described in 1898, shortly after Wilhelm Röentgen discovered x-rays and 
Antoine Becquerel discovered radioactivity as various forms of radiation used to treat cancer 
(20). The distinction between two distinct types of RILI was not made until 1925. Molecular and 
cellular damage occur immediately after tissue exposure to ionizing radiation, yet the clinical and 
physiopathological features are often delayed for weeks, months, or years after treatment. RILI 
leads to compromised lung function, including diffusion and gas exchange, affecting the 
breathing capacity of patients and their overall quality of life (21-23). Clinically significant RILI 
occurs in about 30% of patients receiving thoracic irradiation for lung cancer (24), while 
concurrent chemotherapy increases this incidence (25). 
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Figure 1.2. Dose-response curve for radiation therapy. Radiation therapy treatment schedules 
aim to maximize tumor cure while minimizing normal tissue toxicity. The dotted line represents 
a theoretical dose associated with an optimal therapeutic outcome. The probability of normal 
tissue damage increases with radiation dose. Adapted from Barnett, GC et. al. 2009, Joiner, M.C. 
and Van Der Kogel, A.J. 2009.   
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B. Radiation-induced lung injury: Early and late effects. It is important to make a distinction 
both clinically and biologically between early and late radiation side effects to provide insight 
towards the development of novel therapeutic interventions. Radiation pneumonitis occurs in the 
acute phase, within 4-12 weeks after completion of radiation therapy (26). Clinically, patients 
with pneumonitis present with shortness of breath, chest pain, cough, congestion and fever (27). 
Radiation fibrosis occurs in the late phase, develops within 6-12 months after the completion of 
radiation therapy, and can continue to progress for over 2 years before becoming stable (26). 
Patients may present in the clinic with progressive chronic dyspnea (i.e., difficulty breathing), 
and radiologic findings which are consistent with lung fibrosis and include lung tissue retraction, 
pleural thickening, volume loss, and tracheal deviation toward the irradiated region (28). Thus, 
RILI is classically divided temporally, according to the time of symptom appearance, as either 
the early, acute inflammatory phase or the late, chronic fibrotic phase. These two distinct yet 
closely related phases of RILI are characterized by particular histologic lesions and may occur 
sequentially or independently. 
Radiation-induced pneumonitis and fibrosis is driven by a complex process involving an 
early inflammatory process triggered by damage to lung parenchyma, epithelial cells, vascular 
endothelial cells and stroma that involves induction of pro-inflammatory cytokines and 
chemokines which recruit inflammatory immune cells in the lung tissue resulting in pneumonitis 
and late fibrosis (23, 29, 30). Initially, oxidative injuries after radiation induce expression of pro-
inflammatory cytokines. These ensuing cytokines subsequently mediate the recruitment of 
inflammatory cells into the injured tissue. Infiltrating inflammatory cells are stimulated and 
activated, producing additional mediators, resulting in a cytokine cascade (31, 32). The 
expansion and perpetual activation of inflammatory cells, and components of the lung 
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parenchyma, lead to clinical pneumonitis. Activated cells produce molecular mediators and 
growth factors that affect the proliferation and gene expression of lung fibroblasts (33). This 
process leads to increased collagen synthesis and deposition, eventually leading to the 
development of lung fibrosis. 
C.  Cellular mediators of radiation-induced lung injury. The lung is composed of 
approximately 50 distinct cells types (2). Rube et. al. first formally proposed a multicellular 
cross talk hypothesis involving the interaction of a multitude of cells that reside in a given tissue 
to explain the development and pathogenesis of radiation injury (34). According to this model, 
all cells in the irradiated lung such as endothelial and epithelial cells as well as inflammatory 
cells actively contribute to RILI. Alveolar epithelial cells consist of type I and type II 
pneumocytes (Figure 1.1D). Type I pneumocytes cover more than 90% of the alveolar 
epithelium surface. Type II pneumocytes secrete surfactant and regulate surface tension. 
Radiation-induced apoptosis of type I pneumocytes leads to the proliferation of type II 
pneumocytes, which reduces the regenerative capacity of the alveolar epithelium. In response to 
radiation-induced injury and inflammatory stress, lung fibroblasts differentiate into 
myofibroblasts and this turnover contributes to the formation of scar tissue through the 
generation of collagen, fibronectin, and other ECM components by myofibroblasts (35). Early 
radiation responses in the lung may be driven by activation or damage of lung epithelial or 
endothelial cells, while fibroblasts are likely contributors to late radiation fibrotic responses. The 
interaction of these lung cells with inflammatory cell subsets in the lung after radiation 
undoubtedly plays an important role in the pathology and progression of RILI. 
Studies carried out in immunocompromised mice lacking functional T and B cells 
demonstrate that radiation pneumonitis and fibrosis occur in the absence of functional 
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lymphocytes (36), indicating that cells of the adaptive immune system are not required for the 
induction or promotion of RILI. Rather, innate immune cells appear to be the major contributors 
to the pathology associated with radiation toxicities in the lung, with a particular emphasis on 
macrophages. 
 Given the sheer abundance of macrophages in the lungs in the steady state, it is no 
surprise that these cells are central players in inflammatory, immunoregulatory, and repair 
processes. Alveolar macrophages exhibit a great capacity to functionally contribute to pulmonary 
inflammation and anti-microbial defenses (37). In contrast, interstitial macrophages have been 
shown to have more immunoregulatory roles in the maintenance of lung homeostasis and during 
pathologic conditions (38). It is interesting to note that after thoracic irradiation, macrophages 
are prominently found at inflammatory and fibrotic foci in the lungs (39). 
Classically activated M1 macrophages are generated inflammatory cytokines (TNF-α, 
GM-CSF, IFN-γ) M1 macrophages and mediate acute inflammation, kill intracellular microbes, 
and participate in Th1 reactions. M2 macrophages can be generated through alternative 
activation by IL-4, IL-13, IL-10, TGF-β, or immune complexes, and have an immunosuppressive 
phenotype. M2 macrophages participate in Th2 and Treg reactions (40). M1 macrophages 
produce NOS2, which generates reactive NO species, thus promoting inflammation. M2 
macrophages produce Arg-1, which generates L-orthonine, a precursor of proline, from arginine 
(41). Proline enhances collagen synthesis, thus promoting tissue repair and resolution of 
inflammation (42). The M1 phenotype predominates during the acute inflammatory phase, and 
then switches to M2 during wound-healing phase (43).  
Neutrophils possess potent antimicrobial properties and are the first cells to be recruited 
to sites of inflammation. Neutrophils are known to contribute to acute lung injury (44). However, 
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a specific role for neutrophils in RILI has been unclear.  Myeloperoxidase (MPO) is an abundant 
constituent of activated neutrophils and its presence in tissues is a marker of neutrophil 
recruitment (45). Increases in MPO expression and activity have been detected in irradiated 
lungs (46, 47), suggesting that activated neutrophils contribute to mediating lung damage after 
thoracic irradiation. 
D.  Molecular mediators of radiation-induced lung injury. Radiation disrupts endothelial and 
epithelial cell barrier integrity by interrupting adherens junctions that bind cells together within 
tissues. E-cadherin is an adhesion molecule expressed on epithelial cells (48). Normal expression 
of lung E-cadherin is critical for the maintenance of tight junctions between epithelial cells and 
for maintenance of normal barrier function of airway epithelium. Decreased E-cadherin 
expression in the lung would be indicative of a disrupted epithelial barrier, which can result in 
the recruitment of inflammatory cellular and molecular mediators and drive chronic 
inflammation. 
Direct killing of cells by ionizing radiation releases damage-associated molecular patterns 
(DAMPs) into the extracellular milieu, stimulating an inflammatory response (49). Furthermore, 
irradiation induces pro-inflammatory and chemotactic cytokine gene expression programs in 
lung parenchymal cells, including leukocytes, fibroblasts, endothelial, and epithelial cells. These 
molecular mediators including, IL-1β, IL-6, and TNF-α, can subsequently recruit inflammatory 
cells to the injured tissue or influence the phenotype of resident leukocyte subsets already present 
in the lung, stimulating susceptible cells to further produce cytokines. These levels fluctuate over 
time during the radiation tissue damage response, producing a cyclic cytokine cascade, as 
observed by cycles of increased and decreased cytokine release (30).  
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 During the process of a normal wound healing response, inflammation after tissue injury 
is resolved and ECM breakdown products are removed. . In contrast, lung injury induced by 
radiation leads to lung fibrosis, in which the inflammation is unresolved due to a process akin to 
an aberrant wound healing response (30, 50). Lung fibrosis that occurs after thoracic radiation is 
analogous to a “wound that won’t heal”, since regulatory feedback mechanisms are not observed, 
resulting in inflammatory cells and myofibroblasts that remain constitutively active. These cells 
in irradiated tissue therefore are perpetually receiving tissue repair signals.  
Fibrogenesis and excessive ECM and collagen deposition are key contributors in the 
development of late radiation effects and fibrosis in the lung. Fibrosis is an endpoint in response 
to tissue injury that is characterized by the replacement of normal, functional tissue by collagen-
rich matrix (51). Chronic inflammation in the lung can lead to pulmonary fibrosis. Transforming 
growth factor (TGF-β) is a pleotropic cytokine produced by numerous inflammatory, 
mesenchymal, and epithelial cells (52, 53). TGF-β has a multitude of functions and has been 
implicated in the formation of lung fibrosis (54). Several studies showed potential for TGF-β as a 
serum marker of RILI (55-57); however, their findings were not confirmed by a subsequent 
prospective study that evaluated plasma TGF-β levels (58). Strategies to target TGF-β for the 
mitigation of radiation-induced pulmonary toxicity need to be tested prospectively in the clinic to 
determine if inhibiting this pathway in humans is safe and effective.  
E. Limitations of current management of radiation-induced lung injury. Management 
strategies for RILI can be classified under the following three categories of intervention: 
protection, mitigation, and treatment (59). Protectors are designed to prevent normal tissue 
damage and are administered prior to radiation, while mitigators and treatments are given during 
or after a course of radiation therapy, or after RILI symptoms emerge (60). Despite decades of 
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research, there is a disproportionately low number of radioprotectors presently in use and they 
are limited to selected cancers. Several therapies have been investigated to minimize 
radiotoxicity yet there is currently no known optimal radioprotective therapy for RILI, 
particularly for the treatment of late fibrosis (22, 61). Limitations include the safety profile of 
these agents along with the risk of tumor protection from a desired radiation effect. 
Prospective controlled studies in humans have not been performed to determine the 
efficacy of potential therapies for RILI. Steroid therapy is the current treatment for symptomatic 
patients with subacute onset of RILI, and unfortunately its use is accompanied with extensive 
side effects (62, 63). Glucocorticoids, antibiotics, or heparin may be administered 
prophylactically despite a lack of efficacy in reducing the incidence of radiation pneumonitis (24, 
25, 62), and symptoms tend to recur when therapy is discontinued. Furthermore, patients with 
established radiation-induced fibrosis are unlikely to benefit from glucocorticoid therapy (64).  
A key feature of wound healing and fibrosis, regardless of the cause, is remodeling of the 
extracellular matrix (ECM) and excessive deposition of the ECM component collagen (65). 
Accordingly, therapies that inhibit collagen synthesis such as colchicine, penicillamine, 
interferon-gamma (IFN-γ), or pirfenidone, were thought to potentially alter the progression of 
radiation fibrosis. Currently, it is unknown whether drugs that inhibit collagen synthesis and 
deposition will slow further fibrosis. 
Pentoxifylline has been studied as a treatment for radiation fibrosis. It is a methylxanthine 
derivative that improves microvascular blood flow and inhibits platelet aggregation. In an open 
label drug trial, the effect of oral pentoxifylline was evaluated in patients with soft tissue post-
irradiation fibrosis of the neck, chest wall, pelvis, or extremities (66). Although pentoxifylline 
has immunomodulatory properties mediated by inhibition of pro-inflammatory cytokines (67), 
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particularly TNF-α and IL-1 (68, 69), it was found to be ineffective in the treatment of chronic 
radiation-induced fibrosis. A separate randomized double-blind study of pentoxifylline taken 
orally 3 times a day concomitantly with radiation therapy showed a modest benefit in the 
prevention of radiation-induced pulmonary toxicity, in a small sample size of 16 lung cancer 
patients (70).  
Angiotensin converting enzyme (ACE) inhibitors are a class of drugs primarily used to 
treat hypertension and congestive heart failure by relaxing blood vessels, leading to reduced 
blood pressure and decreased oxygen demand from the heart (71). Captopril, an ACE inhibitor, 
reduced radiation-induced lung fibrosis in a preclinical rat model (72). In a retrospective study 
that included patients that received radiation therapy for lung cancer, ACE inhibitors reduced 
clinically significant acute radiation pneumonitis compared to matched patients not on ACE 
inhibitors (73). Prospective studies must follow up to confirm these findings. Whether ACE 
inhibitors also decrease radiation fibrosis remains to be clinically investigated. 
Amifostine, known as WR-2721 or the trade name Ethyol
®
, is a radioprotector currently 
being investigated as a therapy to reduce the incidence and severity of radiation pneumonitis in 
normal tissues. It was first developed by the Anti-Radiation Drug Development Program of the 
U.S. Army in the 1960’s as a potential agent to protect against ionizing radiation exposure (74). 
Amifostine has been shown to eliminate free radicals in tissues generated by radiation therapy, 
resulting in cytoprotection, and is currently the only radioprotector in clinical use (61). The 
results of randomized studies revealed that this drug is particularly promising for radioprotection 
in patients being treated for head and neck cancers. It is approved for xerostomia (i.e., dry 
mouth) in patients following head and neck irradiation (75). 
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Amifostine is an inactive prodrug that is dephosphorylated by alkaline phosphatase in 
normal endothelium to the active thiol metabolite, WR-1065, which can act as a free radical 
scavenger. The decreased vascularity of the tumor and the differential expression of alkaline 
phosphatase in normal versus malignant tissues contribute to the selective cytoprotective effects 
of amifostine. In a study evaluating a protective role of amifostine for pulmonary toxicities in 
patients with stage II or III NSCLC receiving concurrent chemoradiotherapy, amifostine 
significantly reduced acute pneumonitis in patients receiving radiation therapy (23% vs 3.7%, 
p=0.037) (76). Unfortunately, disadvantages of amifostine include the need for daily intravenous 
infusions, prohibitive price, and associated systemic effects such as severe nausea and vomiting 
which resulted in treatment discontinuation in over 20% of patients enrolled in a phase III 
randomized trial in head and neck cancer (77). 
Understanding the cellular and molecular mechanisms of the inflammatory processes 
involved in RILI may lead to the development of more effective prophylactic and therapeutic 
interventions.  
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III. Soy isoflavones 
A. Beneficial properties of soy. Plant-based foods are a multifaceted assortment of chemicals, 
including both nutrients and biologically active compounds that are nonnutrients (78). The latter 
are referred to as nutraceuticals or phytochemicals. There are records of soy use in China that 
date back to the eleventh century B.C., although the plant did not reach Europe and the United 
States until the 18
th
 century (National Cancer Institute). The soybean is a versatile plant that can 
be processed into a variety of products for dietary consumption including soy milk, miso, tofu, 
soy flour, and soy oil (79). Soy foods contain many phytochemicals that may have health 
benefits, including phytic acid, sterols, saponins, isoflavones, and lignans (80). Among these, soy 
isoflavones have been the significant focus of research due to their possession of a plethora of 
biological activities including anti-inflammatory, antioxidant, chemopreventative, and antitumor 
effects.  
Isoflavones are always present in significant amounts in soybeans and serve an important 
physiologic function for the host. Isoflavones in soybean plants promote infection of plant roots 
by beneficial, mutualistic soil bacteria (81). Soy isoflavones facilitate a symbiotic relationship 
between soybean and Rhizobium bacteria by inducing the transcription of nodulation genes 
expressed in the Rhizobium bacteria. This results in the rhizobia inducing the formation of 
nodules on roots of soybean plants (82). Rhizobia also fix nitrogen which the plant can then use 
for growth. 
Soy isoflavones are known as phytoestrogens due to their similarity in structure to the 
human female hormone 17-β-estradiol, and their ability to bind estrogen receptors in vitro and 
induced estrogen-like effects in vivo (83). However, phytoestrogens have relatively weak 
estrogen activity compared to animal estrogens (84), and isoflavones have a greater affinity for 
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estrogen receptor beta (ER-β) than for estrogen receptor alpha (ER-α) (85). Phytoestrogens such 
as soy isoflavones can also have estrogen receptor antagonist activity by interacting with and 
blocking binding sites from endogenous estrogen (86). Their mode of biological action involve 
both ER-dependent and ER-independent mechanisms. Genistein is the most abundant and 
bioactive soy isoflavone (87). Other isoflavones found in soybeans include daidzein and 
glycitein. Isofavones are also beneficial to the soybean plant as a survival mechanism during 
times of stress due to the antioxidant, antimicrobial, and antifungal properties of these 
phytoestrogens (88). 
The combined effect of multiple isoflavones in preventing or treating cancer compared to 
that of a single isoflavones has been investigated in preclinical studies, by our group and others, 
indicating that administering mixtures of isoflavones increases effectiveness of the individual 
compounds (89, 90). Isoflavones act as chemopreventative agents as suggested by 
epidemiological studies (91-93), and a high-soy diet is associated with a decreased risk of 
prostate cancer (94-96).  
B.  Molecular structures and metabolism. Soy isoflavones are diphenolic compounds that 
share a structural similarity to estrogen, as presented in Figure 1.3 (adapted from (97) and (98)). 
These compounds possess a variety of biological activities including the ability to act as an 
antioxidant. Genistein, in particular, is a potent tyrosine-specific kinase inhibitor (99). This leads 
to its chemoprotectant activities against chronic inflammatory disorders, cancers, and 
cardiovascular disease. 
Isoflavones are present in soybeans primarily as β-glucosides, their inactive form, 
becoming active in the plant when the sugar molecule is cleaved. Soy isoflavones are quite heat-
stable, thus cooking soy foods does not change the total isoflavone content or nutraceutical value 
18 
  
 
(100). Glycosidic isoflavones are not readily bioavailable in humans due to the sugar-binding 
moiety that prevents their crossing through enterocytes, and hydrolysis is required for gut 
absorption and bioavailability. After oral uptake, isoflavones are unconjugated and absorbed by 
the gastrointestinal tract, and can be detected in plasma as soon as 30 minutes after the 
consumption of soy products (101). Intestinal β-glucosidases catalyze hydrolysis of the sugar 
moiety and the gut microflora metabolize the aglycones (102). Unconjugated aglycones are 
produced after hydrolysis, which can be further metabolized into p-ethyphenol (from genistein) 
and equol (from daidzein). During metabolism, formononetin and biochanin A are demethylated 
to daidzein and genistein, respectively (Figure 1.3). The resulting metabolite levels can differ to 
a great extent and depend on the individual microflora. The majority of the absorbed aglycones 
are immediately re-conjugated and have two possible fates: enter circulation to be available to 
the body or return to the intestinal lumen through the portal circulation to be absorbed in the 
large intestine (103). Conjugated isoflavones are no longer functional or bioactive. Only 1% of 
the isoflavones in human plasma are circulating in the active, aglycone form; they are 
predominantly inactive glucuronides (75%) and sulfates (24%), named in reference to their 
conjugates. Isoflavone levels in plasma reach a maximum concentration by 6 hours following 
soy product consumption (101). Once these compounds are in the body they are re-conjugated to 
glucuronides and excreted in the urine. 
Levels of serum isoflavones in our murine studies following treatment with 1 mg/day of a 
mixture of soy isoflavones reflected typical in vivo metabolism with significant levels of 
daidzein (1.6 μM) and genistein (1.7 μM) (90). These levels are comparable to plasma 
concentrations of 1–4 μM soy isoflavones measured in Asian populations consuming foods rich 
in soy isoflavones, in contrast to levels of 10-30 nM found in Western populations (36).  
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Figure 1.3. Molecular structures of soy isoflavones and endogenous 17-β-estradiol 
(estrogen). (A). Structure of isoflavone backbone. (B). The major isoflavones in soybean are 
genistein (50%), daidzein (40%), and glycitein (10%). (C). Biochanin A and formononetin are 
derivatives of genistein and daidzein, respectively. Equol is a breakdown product of daidzein, 
however only ~30-50% of people have the intestinal microbiota to produce equol. (D). Structure 
of the primary female sex hormone, estrogen. Adapted from Kurosu 2011 (97) and Day et. al. 
2002 (98).  
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C. Soy isoflavones and the immune system. The most extensively studied isoflavone in 
respect to effects on the immune system is genistein, which was shown to regulate immune 
function (104). Genistein has been shown to have strong immune modulatory effects on 
macrophages, via inhibition of the production of TNF-α (105). Genistein may also downregulate 
cytokine-induced pro-inflammatory pathways in human brain microvascular endothelial cells 
(106), and soy isoflavones have been shown to have anti-inflammatory mechanism via 
modulation of leukocyte-endothelial cell interactions in a study of atherosclerosis (107). 
  Nuclear factor κB (NF-κB) activation is a molecular common denominator between 
inflammation and cancer (108). This transcription factor is constitutively active in a large 
number of cancers and is critical for tumor cell survival. Our lab has previously shown in tumor 
cells that soy isoflavones target critical survival pathways that are upregulated and constitutively 
activated in cancer cells, including NF-κB, which are responsible for the transcription (109). In 
contrast, normal cells do not constitutively express activated NF-κB, and activation of this 
transcription factor is important for the expression of pro-inflammatory gene programs. 
Differential expression of soy isoflavones targets in tumor cells versus normal cells is a potential 
mechanism of specificity for soy effects in cancer models. 
D. Controversy associated with the use of phytoestrogens. Soy isoflavone intake among 
people in the Western world (0.15-1.7 mg per day) (110-112) is about 100-fold less than that of 
Asians (15-50 mg per day) (113-116). The incidence of breast and prostate cancers is lower 
among Asians compared to people in the Western world (117), thus soy consumption appears to 
be related to the decreased risk of cancer recurrence and/or mortality. 
The first report linking isoflavones and cancer was almost 30 years ago when it was 
shown that genistein is a potent inhibitor of multiple protein tyrosine kinases relevant to cancer 
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cell growth and proliferation (118). The use of soy isoflavones in patients with or at risk of 
developing breast cancer was proposed when they were shown to inhibit the proliferation of 
several types of cancer cells (119). 
Interest in isoflavone metabolism was piqued when it was realized that phytoestrogens 
are capable of disrupting normal endocrine function and their estrogenic properties were 
connected to infertility in animals (120, 121). A well-documented incident involves an outbreak 
of infertility in sheep in Australia that were grazing red clover that contained a high percentage 
of the isoflavone formononetin, which was being metabolized into equol by intestinal bacteria 
(122). When these sheep were switched to a genetically modified clover lacking isoflavones the 
infertility was ameliorated. Interestingly, it has been hypothesized that phytoestrogens may have 
evolved in plants as a protective mechanism by interfering with reproduction of grazing animals 
(97). Despite the detrimental effects of soy isoflavones reported in animal fertility, the effects of 
isoflavones on human reproductive function have not been sufficiently identified. An explanation 
for this discrepancy may lie in the vast difference in isoflavone exposure between animals and 
humans. The amount of isoflavones in the clovers consumed by the Australian sheep that caused 
their infertility was estimated to be about 20-100 g per day, which is up to 2000-fold higher than 
the amount of isoflavones achievable by humans consuming a high soy isoflavone diet (15-50 
mg per day) (123, 124). Therefore, it is not likely that humans on a diet with a typical soy intake 
will achieve comparable levels of biologically active isoflavones to impact fertility, despite the 
ability of phytoestrogens to disrupt the endocrine system in animals and cause infertility. 
There have been numerous prospective epidemiologic statues that have evaluated the 
impact of soy intake on the prognosis of breast cancer survivors after diagnosis (Table 1) (125-
131). A recent meta-analysis of 35 studies in pre- and/or post-menopausal women reporting an 
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association between soy isoflavones intake and breast cancer risk found that there is indeed no 
harmful association between intake of soy isoflavones and breast cancer (132). Taken together, 
the overwhelming evidence to date suggests that soy foods are not harmful for breast cancer 
survivors to consume. There is no evidence-based basis for advising breast cancer patients 
against the consumption of soy foods, further supporting the safety of soy isoflavones.  
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Table 1. Description of epidemiologic studies evaluating the effects of soy intake on breast 
cancer prognosis. Prospective studies in different countries have evaluated the impact of post-
diagnosis soy intake on the prognosis of breast cancer survivors and have overwhelmingly 
concluded that soy isoflavones consumption in breast cancer survivors is safe, and even 
beneficial in some instances. Table adapted from Messina et. al. It’s Time for Clinicians to 
Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients. Oncology 
(2013) (133).  
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E. Soy isoflavones for the treatment of radiation injury. We have previously demonstrated in 
mice receiving a single high dose of thoracic irradiation (Figure 1.4) that soy isoflavones have 
the dual capability of protecting normal lung tissue from radiation injury while simultaneously 
enhancing radiation damage in the tumor (36, 134, 135). In a pre-clinical lung cancer model, 
supplementation with a mixture of soy isoflavones (genistein, daidzein, and glycitein) given pre- 
and post-thoracic irradiation mitigated the vascular damage, inflammation and fibrosis caused by 
high dose radiation injury to lung tissue suggesting that soy can alter the radiation-induced 
inflammatory response (36, 134). In naïve mice, soy protected the lungs against adverse effects 
of radiation including skin injury, hair loss, increased breathing rates, inflammation, pneumonitis 
and fibrosis (135). The soy isoflavone genistein and the superoxide dismutase mimetic EUK-207 
were observed to mitigate radiation-induced lung damage in naïve rats. These compounds 
inhibited late occurring pulmonary fibrosis and reduced levels of activated macrophages and 
TGF-β1 expression (136). 
 These outcomes in naïve mice corroborated our findings in lung tumor models and 
provided further evidence for a radioprotective effect of soy isoflavones. It is important to note 
that soy isoflavones also sensitized cancer cells to radiation both in vivo and in vitro in pre-
clinical tumor models of lung cancer, demonstrating a differential effect of radioenhancement on 
lung tumors with simultaneous radioprotection of normal lung tissue (36, 134, 137). 
In support of a clinical application of soy isoflavones for radioprotection in lung cancer, 
the use of soy isoflavones as radioprotectors was found to be safe in human clinical trials (138). 
Prostate cancer patients receiving radiation therapy and soy tablets had reduced radiation toxicity 
and resulted in improved urinary, sexual and gastrointestinal functions (139). These findings 
suggest that soy isoflavones used as a complementary intervention to radiotherapy for lung 
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cancer could potentially reduce lung toxicity and provide improved therapeutic benefit to 
patients. While the anti-oxidant and disease preventative effects of a soy-rich diet have been 
investigated, an immune-mediated mechanism of radioprotection by soy isoflavones in normal 
tissues remains to be elucidated. 
Alteration of the host immune response by radiation therapy through the triggering of a 
potent inflammatory response is a key contributor to the tissue-damaging pathology of RILI. Soy 
isoflavones may inhibit this inflammatory process or promote tissue repair. The research 
objective of this dissertation is to investigate radioprotection mediated by soy isoflavones in 
normal lung tissue by dissecting the radiation-induced inflammatory response (Figure 1.5). The 
clinical goal is to improve the therapeutic ratio of high-dose radiation therapy on the tumor target 
and reduce the radiation dose-limiting toxicity of radiation therapy to the normal lung.  
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Figure 1.4. Selective delivery of high-dose radiation therapy to lungs. Radiation is delivered 
to the thoracic cage comprising the whole lung. Three anesthetized mice, in jigs, are positioned 
under a 6.4 mm lead shield with 3 cut-outs in an aluminum frame mounted on the X-ray machine 
to permit selective irradiation of the lung in 3 mice at a time, as previously described (134). The 
radiation dose to the lung and the scattered dose to areas of the mouse outside of the radiation 
field are carefully monitored. To minimize backscattering of radiation, the bottom of the 
aluminum frame that holds the jigs was hollowed out and the backplate of the jig was thinned to 
1.6mm thickness. Under these conditions and the lead shielding, the X ray dose to the shielded 
regions was reduced to 1% of the dose to the irradiated field. The dose rate was 101 cGy/min and 
half value layer was 2 mm Cu. Photon irradiation was performed at a dose of 10 Gy with a 
Siemens Stabilipan X-ray set (Siemens Medical Systems, Inc., Erlangen, Germany) operated at 
250 kV, 15 mA with 1 mm copper filtration at a distance of 47.5 cm from the target.  
27 
  
 
 
Figure 1.5. Experimental design and treatment strategy. Mice were pre-treated with oral soy 
isoflavones each day for 3 days at a dose of 5mg/day (equivalent to 250mg/kg). Then, the lung 
was selectively irradiated with 10 Gy.  Soy treatment was continued on a daily basis for 5 more 
days at 5mg/day. Then mice were treated with a lower soy dose of 1mg/day (equivalent to 
50mg/kg), given daily 5 days a week for up to 18 weeks. The rationale for giving a higher dose 
of soy isoflavones for pre-treatment and just after radiation is to optimize the effect of soy, based 
on previous studies (36, 140). At different time points after radiation, separate mice from each 
treatment group were either processed for flow cytometry studies or homogenized for ELISA, 
snap frozen for western blot, or mice were used to fix lungs in situ with formalin for histology 
studies. 
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CHAPTER 2 
Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of 
Radiation-Induced Activation of Macrophages and Neutrophils 
 
ABSTRACT 
 
Thoracic radiotherapy for the treatment of lung cancer is limited by morbidity-associated 
toxicities. Normal lung tissue damage after radiation therapy results from a chronic inflammatory 
response, leading to pneumonitis and fibrosis. Soy isoflavones mitigate inflammatory infiltrates 
and radiation-induced lung injury, but the cellular inflammatory mediators altered during 
radioprotection are unknown. Oral treatment with a mixture of soy isoflavones (genistein, 
daidzein, and glycitein) before and after administration of a high dose thoracic radiation at 10 Gy 
led to a reduction in infiltration and activation of alveolar macrophages and neutrophils in both 
the bronchoalveolar and lung parenchyma compartments. Soy treatment protected F4/80
+
CD11c
-
 
interstitial macrophages which are known to play a regulatory role in inflammation and are 
decreased by radiation. Furthermore, soy isoflavones reduced the levels of nitric oxide synthase-
2 (NOS2) expression but increased arginase-1 (Arg-1) expression in the lung parenchyma after 
radiation, suggesting a switch from pro-inflammatory M1 macrophage to an anti-inflammatory 
M2 macrophage phenotype. Soy also prevented the influx of activated neutrophils in lung caused 
by radiation. The modulation of macrophage and neutrophil responses to radiation by soy 
isoflavones could play a role in the resolution of radiation-induced chronic inflammation in the 
lung. 
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INTRODUCTION 
 
Radiation pneumonitis is caused by an early inflammatory process triggered by damage 
to lung parenchyma, epithelial cells, vascular endothelial cells and stroma. This process involves 
induction of pro-inflammatory cytokines and chemokines which recruit inflammatory immune 
cells to the lung tissue resulting in pneumonitis and late fibrosis (29, 30, 141). Early acute 
pneumonitis occurs by 2-4 months after radiotherapy, while late chronic pneumonitis manifests 
clinically over 6-24 months (21, 23). At late stages, radiation-induced pulmonary fibrosis results 
from aberrant resolution of inflammation in contrast to classical wound healing processes (30). 
These adverse events after radiotherapy affect patients’ breathing and their quality of life. 
Various strategies to decrease the extent of pneumonitis have been investigated but need further 
research efforts (142). 
We have reported in preclinical mouse models that supplementation of soy 
isoflavones with thoracic irradiation mitigates radiation-induced inflammatory cytokines, 
infiltration of inflammatory cells and fibrosis (36, 134, 135), but the cellular mediators of 
radioprotection remain unclear. In Chapter 2, we investigate the role of macrophages and 
neutrophils in the mitigation of radiation-induced inflammatory events by soy isoflavones in lung 
tissue. Macrophages are recruited as a first response to radiation-induced damage in the tumor 
microenvironment or in normal tissues (143). Macrophages play distinct roles in the early versus 
late stages of inflammatory response (144-146). Monocytes can differentiate into functionally 
different macrophage subsets. Inflammatory cytokines (TNF-α, GM-CSF, IFN-γ) generate 
classically activated M1 macrophages that mediate acute inflammation and participate in Th1 
reactions (40). M2 macrophages can be activated by IL-4, IL-13, IL-10, TGF-β, or immune 
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complexes, participate in Th2 and Treg reactions, and promote tumor growth and fibrosis (43, 
147). M1 predominates during acute inflammation, and then switches to M2 during the wound-
healing phase at later stages (43). We tested whether soy influences macrophage skewing to M1 
or M2 subsets, and if this altering of macrophage phenotypes could dictate normal lung response 
to radiation-induced damage. 
Activation and infiltration of neutrophils is a hallmark event in the progression of acute 
lung injury (44), and have been shown to be involved in radiation-induced alveolitis (46). 
Therefore, the effect of soy isoflavones on infiltration and activation status of neutrophils was 
studied after radiation to the lungs. Our findings suggest that soy can inhibit the infiltration and 
activation of macrophages and neutrophils induced by radiation in lung parenchyma. Radiation 
induced a pro-inflammatory M1 macrophage phenotype in lungs, while mice receiving soy 
isoflavones and radiation switched to an anti-inflammatory M2 macrophage subtype. These data 
indicate that soy isoflavones modulate the cellular mediators of the inflammatory response 
induced by radiation.   
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MATERIALS AND METHODS 
 
Mice 
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled 
in animal facilities accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care. The animal protocol was approved by Wayne State University 
Institutional Animal Care and Use Committee.  
 
Soy isoflavones 
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from 
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by 
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda, 
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a 
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by 
DMSO (36, 134, 135). 
 
Lung irradiation 
Radiation was delivered to the thoracic cage comprising the whole lung. Three 
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an 
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3 
mice at a time, as previously described (134). The radiation dose to the lung and the scattered 
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize 
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed 
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out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the 
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the 
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon 
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens 
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper 
filtration at a distance of 47.5 cm from the target. 
 
Experimental design 
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day 
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy.  Soy treatment 
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower 
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 18 weeks. The 
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is 
to optimize the effect of soy, based on previous studies (36, 140). At different time points, 
separate mice from each treatment group were either processed to harvest bronchoalveolar 
lavage (BAL) fluid for differential cell counting and lungs for flow cytometry studies or snap 
frozen for western blot, or mice were used to fix lungs in situ with formalin for histology studies 
as detailed below. 
 
Analysis of immune cells by differential cell counting in BAL fluid and flow cytometry on 
single-cell suspension from lungs 
BAL was performed prior to lung resection at 1, 8, 12, and 18 weeks after irradiation. To 
obtain BAL fluid, phosphate-buffered saline (PBS) was gently instilled into the lungs and 
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withdrawn through an incision of the trachea. The BAL fluid samples were centrifuged at 1500 
rpm for 5 minutes at 4° C and supernatant was discarded. Cells were resuspended in media and 
loaded onto slides using a cytospin centrifuge (Cytospin 3 Cell Preparation System, Thermo 
Shandon, UK). Cell preparations were stained using a DiffQuik staining kit (IMEB Inc., San 
Marcos, CA,) and differential cell counts of leukocyte subsets were performed by counting at 
least 300 nucleated cells (148).  
Following collection of BAL fluids, the same mice provided the lungs for flow cytometry 
studies. Lungs were excised, minced, and digested with 0.4 mg/mL collagenase IV for 45 
minutes at 37° C. Digested lungs were passed through a wire mesh, then a 0.7 μm nylon mesh. 
Red blood cells were removed by incubating in red blood cell lysis buffer for 2 minutes at room 
temperature. Single-cell suspensions obtained from the lungs were incubated with Fc receptor-
blocking antibody (eBioscience, San Diego, CA) prior to staining to reduce non-specific binding. 
For morphological characterization of lung leukocytes, cells expressing the pan-leukocyte 
marker CD45 were sorted by fluorescence-activated cell sorting (FACS) using a BD 
FACSVantage SE (BD Biosciences). CD45
+
 cell subsets were gated according to cell size 
[forward scatter (FSC), x-axis] and granularity [side scatter (SSC), y-axis]. Cell subsets obtained 
from each gate were spun onto slides using a cytospin (Thermo Shandon, Pittsburgh, PA), and 
stained using a DiffQuik staining kit (IMEB Inc., San Marcos, CA). To determine the phenotype 
of immune cells, cells were immunostained using a 5-color fluorophore combination of 
fluorescent antibodies consisting of CD45-APC, CD11b-FITC, F4/80-PE, CD11c-APC-
eFluor780, and Ly6G-PerCp-Cy5.5 (eBioscience). Fixable viability dye eFluor 450 
(eBioscience) was used to exclude dead cells from analysis. Cells were analyzed by flow 
cytometry using a BD LSR II flow cytometer (BD Biosciences, San Jose, CA) in the 
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Microscopy, Imaging and Cytometry Resources Core at Wayne State University School of 
Medicine, followed by analysis on FlowJo v10 software (Tree Star Inc., Ashland, OR).  
 
Immunohistochemistry (IHC) 
Mice were sacrificed and lungs were intratracheally instilled with 10% buffered formalin 
and resected, embedded in paraffin, and sectioned. Sections were blocked with IHC Tek 
Antibody Diluent (IHC World, Woodstock, MD) then incubated with primary purified 
monoclonal antibodies directed against F4/80, nitric oxide synthase 2 (NOS2), arginase-1 (Arg-
1), Gr-1 (Ly6C/Ly6G), and myeloperoxidase (MPO) (Abcam, Cambridge, UK) overnight at 4° 
C. Lung sections were then incubated with biotinylated secondary antibodies (Vector Labs, 
Burlingame, CA) at 1:300 for 1 hour at room temperature. Staining was amplified with the 
avidin-biotin system Vectastain ABC Reagent Kit (Vector Labs) and visualized with the Vector 
DAB Substrate Kit for peroxidase (Vector Labs). Sections were counterstained with IHC-Tek 
Mayer’s Hematoxylin (IHC World, Woodstock, MD) and mounted with Permount mounting 
media (Electron Microscopy Sciences, Hatfield, PA). Macrophage and neutrophil infiltrations in 
the lung tissue after radiation were evaluated on a Nikon E800 microscope (Nikon Inc., Melville, 
NY). Quantitation of the number of F4/80
+
 alveolar macrophages and measurement of the cell 
areas were performed using ImageJ software (NIH, Bethesda, MD) in 10 fields of 40x per slide. 
For quantitation of overall level of staining, whole slide imaging was performed using a slide 
scanner and DensitoQuant analysis (3D Histech). The percentage of positive area was calculated 
as the total number of positive pixels divided by total number of pixels. 
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Preparation of lung tissue protein lysates and western blot analysis 
Mice were sacrificed at 12 weeks post-irradiation. Lungs were resected and snap frozen. 
To prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and homogenized in 
10% w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec, Bergisch, 
Germany). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the protein 
extracts were frozen at -80°C until analysis. For western blot analysis, total lung protein extracts 
(50 µg) were loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to Whatman membranes (GE Healthcare Life 
Sciences, Pittsburgh, PA). Membranes were incubated with anti-myeloperoxidase (MPO) 
antibody (Abcam, Cambridge, MA; 1:1000) overnight at 4°C. Membranes were washed and 
incubated with horseradish peroxidase-conjugated secondary antibody (Vector Labs, 1:2000) at 
room temperature for 1 hour. Immunoreactive protein bands were visualized by SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific, Waltham, MA) and captured on a 
digital imaging system (Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-
actin Ab as a loading control (137).  
 
Statistical analysis 
Data are expressed as mean ± SEM. Comparisons between means of two treatment 
groups were analyzed by two-tailed unpaired Student’s t test using GraphPad Prism version 6.0 
software (GraphPad Software Inc., San Diego, CA). A value of p<0.05 was considered 
statistically significant.  
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RESULTS 
 
Effect of radiation and soy isoflavones on immune cell subsets recovered from 
bronchoalveolar space. We previously demonstrated that soy isoflavones decreased the extent 
of inflammatory infiltrates induced by radiation in lung tissues (36, 134, 135). To identify the 
nature of inflammatory infiltrates in lungs induced by radiation and the effect of soy isoflavones 
on these cells, we first analyzed immune cell subsets recovered from bronchoalveolar lavage 
(BAL) (148). Mice were pre-treated with soy isoflavones for 3 days, and then received 10 Gy 
irradiation administered to the whole lung. Soy treatment was continued for 5 days/week for up 
to 18 weeks and BAL fluids were harvested at early and late time points post-radiation, including 
1, 8, 12 and 18 weeks after radiation. Differential cell counts to identify the morphology of 
immune cells were performed and the percentages of macrophages, neutrophils, and 
lymphocytes were calculated (Figure 2.1).  Activated macrophages presented a morphology of 
enlarged foamy cells (Figure 2.1A, inset) that was clearly distinct from non-activated small 
macrophages and were counted separately. Alveolar macrophages constituted 80% to 90% of 
cells recovered from BAL fluids, and the majority presented as small non-activated macrophages 
in control BAL (Figure 2.1). Soy did not alter the morphology of these macrophages. In contrast, 
as early as one week after radiation, there was a significant decrease from 90.7±0.8% to 
24.1±2.9% in small macrophages compared to control (p<0.0001) with a concomitant significant 
increase from 9.1±0.7% to 75.8±3.0% in enlarged foamy activated macrophages (p<0.0001) 
(Figure 2.1A).  This trend was consistently observed at later time points of 8, 12 and 18 weeks 
after radiation (Figure 2.1B, C, D). The ratios of activated versus non-activated macrophages 
were reversed in BAL fluids from mice treated with radiation and soy. There was a significant 
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increase in non-activated macrophages associated with a concomitant decrease in activated 
enlarged foamy macrophages (p<0.01) that was consistently observed at 8, 12 and 18 weeks after 
radiation and these ratios were comparable to the levels of control mice or mice treated with soy 
alone. For example, at 18 weeks after radiation, there was a significant increase in the percentage 
of enlarged, foamy macrophages to 79.0±6.7% compared with 14.6±5.3% in control (p=0.0003) 
(Figure 2.1D). Soy significantly inhibited this radiation-induced increase to 33.1±8.3% compared 
with radiation alone (p=0.0091) (Figure 2.1D). These data demonstrate that radiation induced a 
rapid activation of macrophages that persisted for a long time as shown at 18 weeks. It should be 
noted that soy consistently inhibited this activation of macrophages over time and the 
macrophage morphology presented as small non-activated macrophages.       
Whereas BAL fluids from healthy untreated mice have undetectable numbers of 
neutrophils and lymphocytes, neutrophil counts showed a significant increase induced by 
radiation at 12 weeks (19.0±2.1%, p<0.0001) which was decreased in radiation and soy 
isoflavones-treated mice (8.4±3.2%, p<0.05) (Figure 2.1C). A measurable increase in BAL 
lymphocytes was also observed after radiation; however, this increase was not seen in radiation 
and soy-treated mice.    
38 
  
 
 
Figure 2.1. Effect of soy isoflavones on immune cells obtained from BAL fluid at different time 
points after radiation. BAL fluids were harvested at early and late time points post-radiation. At 1 week 
(A), 8 weeks (B), 12 weeks (C), and 18 weeks (D) post-radiation, differential cell counts on BAL fluid 
cytospins were performed and the percentages of macrophages, neutrophils, and lymphocytes were 
calculated. The ratios of non-activated macrophages and enlarged, foamy activated macrophages (see 
inset 1A), as well as those of neutrophils and lymphocytes, are shown from BAL fluid obtained from 
treated and control mice. The data are presented as mean ± SEM (n = 3-5 mice/group/time point) and p-
values shown represent significant differences between radiation + soy compared to radiation alone. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, radiation compared to control or radiation + soy 
compared to radiation alone.  
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Flow Cytometry phenotypic analysis of immune myeloid cells infiltrating lung parenchyma 
following treatment with radiation and soy isoflavones. Morphological analysis of the 
immune cell subsets in the bronchoalveolar compartment revealed that radiation caused a switch 
from non-activated to predominantly activated macrophages at 2-4 months after radiation, 
whereas soy isoflavones prevented radiation-induced macrophage activation. To further analyze 
the phenotype of myeloid cells involved in the radioprotection of lungs by soy isoflavones, we 
have also analyzed the lung parenchyma compartment by processing lung tissue into single cell 
suspensions and analysis of immune cell subsets by immunofluorescence staining and flow 
cytometry.   
Lung cell suspensions were immunostained using a 5-color fluorophore combination of 
antibodies directed against CD45, CD11b, F4/80, CD11c, and Ly6G from lungs treated with soy, 
radiation or radiation + soy at 12 weeks after radiation, as detailed in Materials and Methods.  
Macrophages were gated based on differential expression of F4/80 and CD11c to analyze 
interstitial macrophages (IM, F4/80
+
CD11c
-
) and alveolar macrophages (AM F4/80
+
CD11c
+
) 
(Figure 2.2A) (149).  Percentages of F4/80
+
CD11c
-
 IM subsets showed a significant decrease in 
interstitial macrophages induced by radiation compared to control (p<0.05), whereas this 
treatment with soy isoflavones protected this population in irradiated lung tissue (p<0.05) 
(Figure 2.2A). F4/80
+
CD11c
+
 AM subsets did not show difference between treatments (Figure 
2.2A), in contrast to BAL findings that showed an increase in AM by radiation and decrease by 
radiation + soy. The discrepancies between the evaluations of alveolar macrophages in the BAL 
compartment versus the lung tissue compartment could be due to initial lavage of loose alveolar 
macrophages to collect BAL fluid and subsequent processing of lungs for FACS.   Therefore, we 
assume that alveolar macrophages activated by radiation were washed out and recovered in the 
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BAL resulting in no AM increase observed in lung tissue. Further analysis to resolve this 
discrepancy is presented in IHC studies below (Figure 2.3). Neutrophils were gated by 
expression of CD11b, and Ly6G/Gr-1 markers within the CD45
+
 population (Figure 2.2B) (150). 
CD11b
+
Ly6G
+
 neutrophils in lungs are significantly increased after radiation compared to 
control (p=0.01), however supplementation of soy to radiation did not significantly change the 
percent of neutrophils (Figure 2.2B).   
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Figure 2.2. Flow cytometry analysis of macrophages and neutrophils isolated from lung tissues. (A). 
Interstitial and alveolar macrophages analysis. At 12 weeks after radiation, lungs from control (Con) 
mice, and mice treated with soy (Soy), radiation (Rad) or radiation + soy (R+S) were dissociated into 
single cell suspensions.  Cells were stained with anti-CD45, anti-F4/80, and anti-CD11c fluorescent 
antibodies to analyze interstitial (F4/80
+
CD11c
-
) and alveolar (F4/80
+
CD11c
+
) tissue macrophages within 
CD45
+
 leukocyte populations by flow cytometry.  Representative flow cytometry plots are presented, 
showing the gating strategy of CD45
+
 myeloid lung cells for analysis of F4/80
+
CD11c
-
 interstitial 
macrophages (IM in pink rectangle gate) and F4/80
+
CD11c
+
 alveolar macrophage (AM in pink circle 
gate). Percentages of F4/80
+
CD11c
-
 IM subsets and F4/80
+
CD11c
+
 AM subsets within CD45
+
 cells are 
shown for lungs from control and treated mice. The data are presented as mean ± SEM (n = 4-5 
mice/group) and are representative of three separate experiments. (B). Analysis of CD45
+
CD11b
+
Ly6G
+
 
neutrophils.  Cells were stained with fluorescent anti-CD45, anti-CD11b, and anti-Ly6G to analyze 
neutrophil subsets by flow cytometry. Representative flow cytometry plots are presented, showing the 
gating strategy for analysis of CD11b
+
Ly6G
+
 neutrophils within CD45
+
 leukocyte populations. 
Percentages of CD11b
+
Ly6G
+
 neutrophils within CD45
+
 cells are shown for lungs from control and 
treated mice. The data are presented as mean ± SEM (n = 5 mice/group) and are representative of two 
separate experiments. *p<0.05, radiation compared to control or radiation + soy compared to radiation 
alone.  
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Skewing toward anti-inflammatory M2 macrophage phenotype in lung tissue treated with 
radiation and soy. The macrophages recovered from BAL fluids obtained from radiation + soy-
treated mice showed a morphology of small non-activated cells in contrast to the enlarged foamy 
activated macrophages obtained from radiation-treated mice. To further study whether soy 
inhibits the activation of macrophages induced by radiation, we investigated, in situ in the lung 
tissues, macrophage subsets and their functional status in lungs treated with radiation only and 
radiation + soy. Lung tissue sections were stained by IHC with the pan-macrophage marker 
F4/80. We have previously documented that pneumonitis caused by radiation injury to lung 
tissue is associated with thickening of alveolar septa and inflammatory infiltrates (36, 134, 135). 
The architecture of the alveolar septa in soy + radiation-treated lungs was thinner akin to control 
lung tissue showing decreased pneumonitis compared to radiation–treated lungs (Figure 2.3A), 
as previously shown (134, 135). Radiation caused a striking infiltration of F4/80
+
 macrophages 
in lungs that was observed in areas of thickened lung alveolar septa, and was more prominent at 
18 weeks after radiation (Figure 2.3A, arrowheads) compared to earlier times points after 
radiation (data not shown). Numerous alveolar macrophages were particularly enlarged with 
abundant cytoplasm showing the morphology of activated macrophages compared to small 
macrophages in control lungs (Figure 2.3A, see arrows and inset). Lungs from mice treated with 
radiation + soy had a lower density of F4/80
+
 macrophages at 18 weeks after radiation compared 
to radiation–treated lungs (Figure 2.3A). Moreover, the morphology of the alveolar macrophages 
was much smaller than those of radiation-treated lungs (see insets, Figure 2.3A). Quantitation of 
F4/80
+
 cells showed that there was a significant increase in the number of alveolar macrophages 
in lungs treated with radiation compared to control lungs (p<0.001, Figure 2.3B). Irradiated mice 
supplemented with soy isoflavones showed a significantly reduced number of alveolar 
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macrophages compared to radiation alone (p<0.001, Figure 2.3B), to levels similar to those of 
control mice. Measurements of the average size of the alveolar macrophages showed that 
radiation increased the size of these cells significantly compared to either radiation + soy 
(p<0.01, Figure 2.3C) or control (p<0.0001, Figure 2.3C).  
To further clarify the functional phenotype of infiltrating macrophages, the NOS2 
activation marker for M1 macrophages and Arg-1 activation marker for M2 macrophages were 
used to differentiate between pro-inflammatory M1 macrophage phenotype and anti-
inflammatory M2 macrophage phenotype. Radiation caused a prominent increase in NOS2 
staining of lung tissue by 18 weeks after radiation (Figure 2.4A), that was apparent in enlarged 
alveolar macrophages (Figure 2.4A, inset). These findings were confirmed by slide scanning 
quantitation for the level of staining (Figure 2.4B). In contrast, a lower level of NOS2 staining 
was observed following radiation + soy (Figure 2.4A, B). Staining of lungs with Arg-1 showed a 
prominent increase in radiation + soy treated lungs compared to radiation alone (Figure 2.4C, D). 
In situ staining revealed that radiation caused an increase in a pro-inflammatory M1 
macrophage phenotype defined by high NOS2 and low Arg-1 levels at 18 weeks after radiation 
(Figure 2.4A, B). This is in contrast to relatively low NOS2 levels and high Arg-1 levels 
observed in lungs treated with radiation + soy or in controls (Figure 2.4B, C).   
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Figure 2.3. In situ detection of alveolar macrophages in lungs treated with radiation and soy 
isoflavones at 18 weeks post-radiation. Lung tissue sections were obtained from control (Con) mice and 
mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 18 weeks after radiation. Sections were 
stained by IHC for the marker F4/80 to detect alveolar macrophages in situ in the lungs. Arrows indicate 
positive staining of F4/80
+
 alveolar macrophages. (A). Radiation caused a marked increase in 
macrophages in thickened alveolar septa areas (arrowheads). Numerous alveolar macrophages were 
particularly enlarged with abundant cytoplasm showing the morphology of activated macrophages 
compared to small macrophages in control lungs (see inset). The density of F4/80
+
 macrophages was 
much lower in radiation + soy treated lungs at 18 weeks after radiation compared to radiation–treated 
lungs. Alveolar macrophages were smaller, resembling those of control lungs (see inset) and the 
architecture of the alveolar septa was thinner akin to control lung tissue showing decreased pneumonitis 
compared to radiation–treated lungs. (B). Using ImageJ analysis of IHC slides, the numbers of F4/80+ 
alveolar macrophages were counted in 10 fields of 40x per slide and the average number of F4/80
+
 cells 
per field ± SEM is reported for each treatment group. (C). Measurement of the F4/80
+
 alveolar 
macrophage cell areas were performed using ImageJ software in 10 fields of 40x per slide and the average 
cell area of macrophages per field ± SEM in each treatment group is reported. The total number of 
macrophages counted and measured in 10 fields were 125 for control, 285 for radiation, and 101 for 
radiation + soy-treated mice.  The means are reported in (B) and (C). All magnifications are at 40x and 
insets at 100x to reveal the extent of positive staining and morphology of immune cell subsets. **p<0.01, 
***p<0.001, ****p<0.0001, radiation compared to control or radiation + soy compared to radiation alone.  
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Figure 2.4. In situ detection of NOS2 and Arg-1 functional macrophage markers in lungs 
treated with radiation and soy isoflavones. Lung tissue sections were obtained from control 
(Con) mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 18 weeks after 
radiation. Sections were stained by IHC for the markers NOS2 and Arg-1 to determine 
macrophage activation status in situ in the lungs. (A). NOS2 staining revealed an abundance of 
activated macrophages caused by radiation presenting as clusters of enlarged NOS2
+
 cells in 
areas of pneumonitis (see insets). Lower levels of NOS2
+
 macrophages were seen in lungs of 
mice treated with radiation + soy treated lungs or control which presented as smaller cells (see 
inset). (B). Whole slide scanning for quantitation of NOS2 positive staining confirmed these 
findings. (C). Compared to radiation, Arg1 expression was greater with radiation + soy. (D). 
Whole slide scanning for quantitation of revealed higher levels of Arg-1 in radiation + soy 
compared to low levels after radiation alone. For analysis of whole slide scanning, the percentage 
of positive area was calculated as the total number of positive pixels divided by total number of 
pixels. All magnifications are at 40x and insets at 100x to reveal the extent of positive staining 
and morphology of immune cell subsets.  
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Radiation-induced infiltration and activation of granulocytes/neutrophils in lung tissue is 
decreased by soy isoflavones. Analysis of BAL immune cells showed an increase in neutrophils 
by 12 weeks after radiation. In situ detection of granulocyte/neutrophil phenotype and function 
were performed by IHC staining of lung tissue sections for Gr-1 (Ly6C/Ly6G) and the neutrophil 
marker NIMP at 12 weeks after radiation. Radiation caused a pronounced increase in clusters of 
Gr-1
+
 granulocytes in areas of thickened septa at 12 weeks after radiation (Figure 2.5, see inset). 
In contrast, following radiation + soy the alveolar septa were not as thickened and contained 
much lower levels of Gr-1
+
 cells (Figure 2.5). NIMP staining for neutrophils followed the same 
patterns with increased neutrophil infiltrates induced by radiation and decreased by radiation + 
soy (Figure 2.5). 
Concurrent with increased infiltration of Gr-1
+
 and NIMP
+
 cells, lungs treated with 
radiation also showed multiple cells with intense MPO staining (Figure 2.6).  MPO
+
 cells formed 
clusters in areas of thickened alveolar septa, which are indicative of a massive infiltration of 
activated neutrophils, as confirmed by quantitative analysis of the level of positive staining 
(Figure 2.6A, B). However, MPO
+
 infiltrates were greatly reduced in lungs treated with radiation 
+ soy (Figure 2.6A, B). These data indicate that radiation-induced neutrophil activation in lung 
tissue is inhibited by soy isoflavones. These findings were confirmed by western blot analysis of 
MPO expression in lung tissue lysates showing an increase induced by radiation, which was 
inhibited by the addition of soy isoflavones (Figure 2.6C).   
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Figure 2.5. Effect of soy isoflavones on radiation-induced infiltration of 
granulocytes/neutrophils in lung tissue. Lungs tissue sections were obtained from control 
(Con) mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 12 weeks after 
radiation. Sections were stained by IHC for Gr-1 (Ly6C/Ly6G) and NIMP to detect 
granulocytes/neutrophils. Staining of Gr-1
+
 granulocytes showed that radiation caused a 
pronounced increase in clusters of granulocytes in areas of thickened septa at 12 weeks after 
radiation (see inset). In contrast, following radiation + soy treatment the alveolar septa were not 
as thickened and much lower levels of positive cells for Gr-1 were observed. All magnifications 
are at 40x and insets at 100x to reveal the extent of positive staining and morphology of immune 
cell subsets.  
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Figure 2.6. Inhibition of radiation-induced activation of neutrophils in lung tissue. Lungs 
tissue sections were obtained from control (Con) mice and mice treated with radiation (Rad) or 
radiation + soy (Rad+Soy) at 12 weeks after radiation. (A, B). Sections were stained by IHC for 
the neutrophil activation marker myeloperoxidase (MPO). Radiation caused extensive MPO 
staining in the lung tissue that is indicative of activated neutrophil infiltration. MPO
+
 activated 
neutrophils were present in clusters in areas of thickened alveolar septa (see inset) at 12 weeks 
after radiation. The levels of MPO were greatly reduced in radiation + soy treated lungs.         
(B). Whole slide scanning for quantitation of MPO positive staining confirmed these findings. 
For analysis of whole slide scanning, the percentage of positive area was calculated as the total 
number of positive pixels divided by total number of pixels. NIMP
+
 neutrophils were also 
increased in lung tissue by radiation, but not by radiation + soy. All magnifications are at 40x 
and insets at 100x to reveal the extent of positive staining and morphology of immune cell 
subsets. (C). Western blot analysis of MPO on whole tissue lysates obtained from lungs showed 
an increase induced by radiation, which was inhibited by the addition of soy isoflavones. Band 
intensities were quantified using ImageJ (NIH) densitometry analysis.  
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DISCUSSION 
 
Soy isoflavones can reduce the extent of inflammatory infiltrates and vascular damage 
caused by radiation in the lungs (36, 134, 135), suggesting that soy modulates immune responses 
triggered by injury. Studies on the effect of soy and the immune system in other diseases besides 
cancer also support this hypothesis. A recent study suggested that genistein may down-regulate 
cytokine-induced pro-inflammatory pathways in human brain microvascular endothelial cells 
(106). Soy isoflavones have been shown in vitro to have anti-inflammatory mechanisms via 
modulation of leukocyte-endothelial cell interactions (107). The goals of our current study were 
to determine whether soy isoflavones modulate innate immune cells putatively involved in 
radiation-induced inflammation in normal lungs by examining the bronchoalveolar space and 
lung parenchyma compartments. 
Macrophages are recruited as a first response to radiation-induced damage in the tumor 
microenvironment in irradiated tissues (143, 151). Alterations in lung macrophages after 
radiation have been observed during early and late phases of tissue injury (152, 153) supporting 
the idea that macrophage activation contributes, at least partially, to the pathogenesis of 
radiation-induced lung injury. Therefore, modulation of the response of macrophages to radiation 
could be a mechanism of radioprotection by soy isoflavones. By 2-4 months after radiation, an 
increase in the number and size of macrophages was observed both in the bronchoalveolar space 
and lung parenchyma compartments, indicative of macrophage activation, confirming previous 
reports (152, 153). Soy isoflavones durably decreased the frequency and size of macrophages 
found in the lung after radiation. 
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Our flow cytometry analysis of lung parenchyma after lavage identified subsets of 
residual F4/80
+
CD11c
+
 alveolar macrophages and F4/80
+
CD11c
-
 interstitial macrophages, as 
previously described by others (154). A decrease in interstitial macrophages was induced by 
radiation, whereas this cell subset was protected by the addition of soy isoflavones to radiation 
treatment. Interstitial macrophages have been shown to have more immunoregulatory roles in the 
maintenance of lung homeostasis and in pathologic conditions (38). Soy could potentially inhibit 
inflammatory responses by protecting interstitial macrophages. In contrast, alveolar macrophages 
exhibit a greater capacity to functionally contribute to pulmonary inflammation and anti-
microbial defense (37). In our present study, soy isoflavones inhibited alveolar macrophage 
infiltration and activation induced by radiation, a mechanism that could play a role in controlling 
inflammatory processes. These findings suggest that soy modulation of macrophage subset 
functions in response to radiation may play a critical role in soy-mediated radioprotective effects 
in lungs. We have further studies ongoing to clarify the role of interstitial and alveolar 
macrophages in radiation-induced lung inflammation and their regulation by soy isoflavones. 
In radiation-treated lungs, our analysis of myeloid cells in situ by IHC showed extensive 
infiltration of inflammatory cells at sites of pneumonitis, consisting of macrophages and 
neutrophils in the lungs. Both types of immune cells were morphologically and molecularly in a 
status of activation. In contrast, soy supplementation to radiation decreased both the infiltration 
and activation of myeloid cells. The influence of soy isoflavones on M1 and M2 macrophage 
polarization in irradiated lungs could be a mechanism of radioprotection. Macrophages possess 
the plasticity to respond to environmental stressors in tissues that functionally range from M1 
pro-inflammatory to M2 immunosuppressive, anti-inflammatory phenotypes (41, 155). These 
two phenotypes can be distinguished by expression of NOS2 and Arg-1 (156). Normal tissue 
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exposed to ionizing radiation generates “damage” signals and type 1 cytokines, such as IL-1β, 
IL-6, and TNF-α, that classically activate macrophages (M1) and drive the acute/chronic 
pulmonary inflammation induced by radiation (157, 158). M1 macrophages produce NOS2, 
which generates reactive NO species, thus promoting inflammation. Alternatively activated 
macrophages (M2) can be generated by type 2 cytokines, such as IL-4, IL-10, and TGF-β, and 
are important for the resolution of inflammation (155, 159, 160). M2 macrophages produce Arg-
1, which generates L-orthonine, a precursor of proline, from arginine (41).  Proline enhances 
collagen synthesis, thus promoting tissue repair and resolution of inflammation (42). Our studies 
now demonstrate that radiation induced a pro-inflammatory M1 phenotype in lungs at late time 
points, while mice receiving soy isoflavones and radiation switched to an anti-inflammatory M2 
subtype with increased levels of Arg-1 and decreased NOS2. These data indicate that soy 
isoflavones supplementation to radiation could result in skewing of alveolar macrophages from a 
pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype, which has been 
found to mediate the resolution of inflammation, including healing and decreased fibrosis. These 
data are in agreement with our previous findings demonstrating that soy isoflavones inhibited the 
release of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IFN-γ which are 
induced by radiation in lung tissues and promote an M1 macrophage phenotype (134).  
Infiltration and activation of neutrophils into the lung are key factors that occur after 
damage to lung tissue (44, 152). Therefore, inhibition of the inflammatory neutrophil response 
induced by radiation in the pulmonary environment may result in reduced host tissue damage. 
Our flow cytometry studies of lung single cell suspensions showed that CD11b
+
Ly6G
+
 
neutrophils were increased after radiation. Immunostaining of lung tissue sections confirmed 
clusters of neutrophils in sites of pneumonitis caused by radiation. These neutrophils were 
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activated, as confirmed by MPO staining. Treatment with soy isoflavones inhibited radiation-
induced neutrophil infiltration and activation, suggesting a mechanism of protection from tissue 
damage by soy.  
In summary, our pre-clinical study in lung suggests that a radioprotective mechanism of 
soy isoflavones could involve inhibition of infiltration and activation of macrophages and 
neutrophils in irradiated lungs. Furthermore, soy caused a polarization from M1 to M2 
macrophage that could play a role in the resolution of radiation-induced acute/chronic 
inflammation in the lungs. It was interesting to note that soy had a protective effect on regulatory 
interstitial macrophages that could participate in maintaining lung homeostasis and control 
inflammation and tissue damage.   
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CHAPTER 3 
Soy Isoflavones Mediate Radioprotection of Normal Lung Tissue by Promoting CD11b
+
 
Granulocyte-Associated Arginase-1 
 
ABSTRACT 
 
Radiation therapy for lung cancer causes normal tissue injury, including pneumonitis and 
fibrosis. We have shown that treatment with soy isoflavones mitigates radiation-induced lung 
injury, but the cellular and molecular mediators of radioprotection remain unclear. We 
hypothesize that soy isoflavones reduce radiation injury by promoting an anti-inflammatory 
phenotype in myeloid cells early in irradiated lung tissue. This chapter investigates the role of 
arginase-1 (Arg-1) associated with CD11b
+
 granulocytes that could act as an immunosuppressive 
molecule involved in soy-mediated radioprotection of lung tissue. BALB/c mice received a 
single 10 Gy dose of thoracic irradiation with a mixture of soy isoflavones (83% genistein, 15% 
daidzein, 0.3% glycitein) given orally at 1 mg/day continuously. Lungs were harvested at 1 week 
post-radiation and Arg-1 was detected by Western blot and immunohistochemistry. The 
phenotype of lung myeloid cells associated with intracellular Arg-1 expression was analyzed by 
flow cytometry. Subsequent IL-1β, IL-6, and TNF-α production in lungs was measured at 4 
weeks post-radiation by ELISA as readout for immunosuppression. At 1 week after radiation, 
both Western blot and immunohistochemistry showed that while Arg-1 levels in lung tissue are 
decreased by radiation, the level is maintained in radiation + soy treated lungs. Radiation and/or 
soy do not affect the percentage of lung CD11b
+
 myeloid cells. However, radiation decreases the 
percentage of CD11b
+
Arg-1
+
 cells in lungs (p=0.0028), whereas soy isoflavones combined with 
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radiation caused an increase in CD11b
+
Arg-1
+
 cell subset (p=0.0096). Radiation decreases the 
percentage of granulocytes expressing CD11b
+
Ly6C
-
Ly6G
+
Arg-1
+ 
(p=0.0050), while these Arg-
1
+
 granulocytes were not reduced in radiation + soy treated lungs (p=0.0032). At 4 weeks, soy 
inhibited increases in IL-1β, IL-6, and TNF-α pro-inflammatory cytokines induced by radiation 
in the lung. Radioprotection by soy isoflavones involves an early process of immunosuppressive 
events that subsequently causes a decrease downstream inflammatory cytokine expression and 
tissue damage by promoting Arg-1
+
 granulocytes in lungs.  
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INTRODUCTION 
 
Radiation pneumonitis is caused by an early inflammatory process triggered by lung 
tissue damage. This process occurs immediately after radiation and induces the expression and 
release of pro-inflammatory cytokines and chemokines which drive the recruitment of 
inflammatory cells into the injured tissue (29, 30, 141). Infiltrating inflammatory cells are 
stimulated and activated, producing additional mediators, resulting in a cytokine cascade (31, 
32). The expansion and perpetual activation of inflammatory cells, as well as lung parenchyma, 
leads to clinical pneumonitis.  
 Inflammation is causally linked to radiation pneumonitis severity and outcome. In 
Chapter 2, our findings suggest that one radioprotective mechanism of soy isoflavones involves 
the inhibition of infiltration and activation of macrophages and neutrophils in irradiated lungs. 
On the other side of the pro/anti-inflammatory radioprotection axis, soy isoflavones may 
promote immunosuppressive phenotypes and anti-inflammatory molecular mediators after 
injury. Thus one possible mechanism of radioprotection in lung tissue could be achieved by the 
indirect suppression of radiation-induced pro-inflammatory cells and pathways. In Chapter 3, we 
investigate the role of myeloid-derived suppressor cells (MDSCs) and their expression of 
arginase-1 in the mitigation of radiation-pro-inflammatory cytokines by soy isoflavones in lung 
tissue to understand the role of immunosuppressive subsets and mediators in radioprotection of 
lung tissue by soy isoflavones.   
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MATERIALS AND METHODS 
 
Mice 
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled 
in animal facilities accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care. The animal protocol was approved by Wayne State University 
Institutional Animal Care and Use Committee.  
 
Soy isoflavones 
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from 
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by 
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda, 
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a 
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by 
DMSO (36, 134, 135). 
 
Lung irradiation 
Radiation was delivered to the thoracic cage comprising the whole lung. Three 
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an 
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3 
mice at a time, as previously described (134). The radiation dose to the lung and the scattered 
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize 
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed 
57 
  
 
out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the 
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the 
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon 
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens 
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper 
filtration at a distance of 47.5 cm from the target. 
 
Experimental design 
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day 
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy. Soy treatment 
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower 
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 4 weeks. The 
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is 
to optimize the effect of soy, based on previous studies (36, 140). At different time points, 
separate mice from each treatment group were either processed for flow cytometry studies or 
homogenized for ELISA, snap frozen for western blot, or mice were used to fix lungs in situ with 
formalin for histology studies as detailed below. 
 
Analysis of MDSC subsets and intracellular Arg-1 by flow cytometry on single-cell 
suspensions of lungs 
Following a BAL wash, lungs were excised, minced, and digested with 0.4 mg/mL 
collagenase IV for 45 minutes at 37° C. Digested lungs were passed through a wire mesh, then a 
0.7 μm nylon mesh. Red blood cells were removed by incubating in red blood cell lysis buffer 
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for 2 minutes at room temperature. Single-cell suspensions obtained from the lungs were 
incubated with Fc receptor-blocking antibody (eBioscience, San Diego, CA) prior to staining to 
reduce non-specific binding. To determine the phenotype of immune cells, cells were 
immunostained using a 4-color fluorophore combination of antibodies consisting of CD45-APC, 
CD11b-PE, Ly6C-PE-Cy7, Ly6G-PE-Cy5.5 (eBioscience). Cells were fixed with 4% 
paraformaldehyde in PBS and incubated with intracellular Arg-1 purified antibody (1:50, BD 
Biosceinces, San Jose, CA). Cells were washed in 1X Permeabilization Buffer (eBioscience) and 
incubated with and additional fluorescent rat anti-mouse IgG1-FITC secondary antibody (BD 
Pharmingen). Fixable viability dye eFluor 450 (eBioscience) was used to exclude dead cells from 
analysis. Cells were analyzed by flow cytometry using a BD LSR II flow cytometer (BD 
Biosciences, San Jose, CA) in the Microscopy, Imaging and Cytometry Resources Core at 
Wayne State University School of Medicine, followed by analysis on FlowJo v10 software (Tree 
Star Inc., Ashland, OR).  
 
Preparation of lung tissue protein lysates and western blot analysis 
Mice were sacrificed at 1 week post-irradiation. Lungs were resected and snap frozen. To 
prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and homogenized in 10% 
w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec, Bergisch, Germany). 
The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the protein extracts were 
frozen at -80°C until analysis. For western blot analysis, total lung protein extracts (90 µg) were 
loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to Whatman membranes (GE Healthcare Life Sciences, Pittsburgh, PA). 
Membranes were incubated with anti-arginase-1 (Arg-1) antibody (eBioscience, San Diego, CA; 
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1:200) overnight at 4°C. Membranes were washed and incubated with horseradish peroxidase-
conjugated secondary antibody (Vector Labs, 1:2000) at room temperature for 1 hour. 
Immunoreactive protein bands were visualized by SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, Waltham, MA) and captured on a digital imaging system 
(Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-actin Ab as a loading 
control (137). 
 
Immunohistochemistry (IHC) 
Mice were sacrificed at 1 week post-irradiation and lungs were intratracheally instilled 
with 10% buffered formalin and resected, embedded in paraffin, and sectioned. Sections were 
blocked with IHC Tek Antibody Diluent (IHC World, Woodstock, MD) then incubated with 
primary purified monoclonal antibodies directed against arginase-1 (Arg-1) (eBioscience, San 
Diego, CA) overnight at 4° C. Lung sections were then incubated with biotinylated secondary 
antibodies (Vector Labs, Burlingame, CA) at 1:300 for 1 hour at room temperature. Staining was 
amplified with the avidin-biotin system Vectastain ABC Reagent Kit (Vector Labs) and 
visualized with the Vector DAB Substrate Kit for peroxidase (Vector Labs). Sections were 
counterstained with IHC-Tek Mayer’s Hematoxylin (IHC World, Woodstock, MD) and mounted 
with Permount mounting media (Electron Microscopy Sciences, Hatfield, PA). Arg-1 expression 
in lung tissue after radiation was evaluated on a Nikon E800 microscope (Nikon Inc., Melville, 
NY).  
 
Enzyme-linked immunosorbant assay (ELISA) 
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Mice were sacrificed at 4 weeks post-irradiation. Lungs were resected and snap frozen. 
To prepare lung homogenates, frozen lungs were thawed, weighed, and homogenized in 10% 
w/v of phosphate buffered saline (PBS) with Complete Protease Inhibitor Cocktail Tablets 
(Roche Diagnostics, Indianapolis, IN) using a gentleMACS tissue dissociator (Miltenyi Biotec, 
San Diego, CA). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the 
supernatant was frozen at -80°C. Lung homogenates were assayed for IL-1β, IL-6, and TNF-α, 
using the respective Ready-SET-GO ELISA kits (eBioscience, San Diego, CA) according to 
manufacturer’s instructions. 
 
Statistical analysis 
Data are expressed as mean ± SEM. Comparisons between means of two treatment groups 
were analyzed by two-tailed unpaired Student’s t test using GraphPad Prism version 6.0 software 
(GraphPad Software Inc., San Diego, CA). A value of p<0.05 was considered statistically 
significant.  
61 
  
 
RESULTS 
 
Effect of radiation and soy isoflavones on Arg-1 levels in lung tissue. Lungs tissue sections 
were obtained from control mice and mice treated with radiation or radiation + soy at 1 week 
post-irradiation and stained by IHC for Arg-1 to detect expression in situ. In control lungs, Arg-
1
+
 cells are evenly distributed across alveolar septa (Figure 3.1A). However, Arg-1
+
 cells were 
sparsely found in areas of thickened septa and staining was overall greatly reduced in lungs 
treated with radiation (Figure 3.1A). Staining of lungs from mice receiving soy isoflavones in 
conjunction with radiation revealed a degree of Arg-1 positivity that was similar to control lungs 
(Figure 3.1A). These data indicate that radiation caused the depletion of Arg-1
+
 cells normally 
occurring the lung, or reduced the expression of Arg-1 in cells in the lung tissue, while soy 
isoflavones protected from this radiation effect. These findings were confirmed by western blot 
analysis of Arg-1 expression in lung tissue lysates showing a decrease induced by radiation, 
which was inhibited by the addition of soy isoflavones (Figure 3.1B, C).   
62 
  
 
 
Figure 3.1. In situ detection of Arg-1 in lung tissue treated with radiation and soy 
isoflavones at 1 week post-irradiation. Lungs tissue sections were obtained from control (Con) 
mice and mice treated with radiation (Rad) or radiation + soy (Rad+Soy) at 1 week after 
radiation. (A). Sections were stained by IHC for Arg-1 to detect expression in situ. Staining of 
Arg-1
+
 cells showed that radiation caused a pronounced decrease in these cells in areas of 
thickened septa at 1 week after radiation. In contrast, following radiation + soy treatment, higher 
levels of positive cells for Arg-1 were observed and were comparable to levels in control mice. 
Secondary antibody alone is shown as a staining control. All magnifications are at 40x. (B). 
Western blot analysis of Arg-1 on whole tissue lysates obtained from lungs showed an increase 
induced by radiation, which was inhibited by the addition of soy isoflavones. (C). Band 
intensities were quantified using ImageJ (NIH) densitometry analysis. Radiation + Soy (R+S).  
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Effect of radiation and soy isoflavones on Arg-1 expression in CD11b
+
 myeloid cell 
compartment in lung tissue. We examined myeloid cells in the lung to determine if this 
arginase-expressing population was being altered by radiation or soy isoflavones treatment. Lung 
cell suspensions were immunostained using antibodies directed against CD45 and CD11b, as 
well as intracellular Arg-1 from lungs treated with soy, radiation or radiation + soy at 1 week 
after radiation, as detailed in Materials and Methods. Intracellular Arg-1 expression in CD11b
+
 
myeloid cells in the lung was evaluated (Figure 3.2). 
Radiation and/or soy isoflavones treatment did not affect the percentage of CD11b
+
 cells 
in the lung at 1 week post-radiation (Figure 3.3A). However, radiation significantly decreased 
the percentage of Arg-1
+
 cells within the CD11b
+
 cellular compartment in lungs (p=0.0228) 
compared to control  (Figure 3.3B), while lungs from Rad+Soy mice show significantly 
increased percentages of CD11b
+
Arg-1
+
 cells (p=0.0096) compared to radiation alone (Figure 
3.3B).  
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Figure 3.2. Gating strategy for the detection of intracellular Arg-1 in CD11b
+
lung 
leukocytes. Single-cell suspensions obtained from the lungs were analyzed. Fixable viability dye 
eFluor 450 was used to exclude dead cells from analysis and gate on live cells. Side scatter are 
(SSC-A) and side scatter width (SSC-W) were used to identify single cell events (singlets). 
CD45
+
 lung leukocytes were gated on, followed by gating on CD11b
+
 cells within this leukocyte 
gate. Intracellular Arg-1 cells were gated on within the CD11b
+
 lung leukocytes.  
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Figure 3.3. Effect of soy isoflavones on intracellular Arg-1 levels in CD11b
+
 leukocytes in 
lung at 1 week post-radiation. (A). Analysis of CD45
+
CD11b
+
 leukocytes in lung. At 1 week 
after radiation, lungs from control (Con) mice, and mice treated with soy (Soy), radiation (Rad) 
or radiation + soy (R+S) were dissociated into single cell suspensions. Cells were stained with 
anti-CD45, anti-CD11b, anti-Ly6C, and anti-Ly6G fluorescent antibodies to analyze CD11b
+
 
myeloid cells within CD45
+
 leukocyte populations by flow cytometry. Percentages of CD11b
+
 
cells within CD45
+
 cells are shown for lungs from control and treated mice. The data are 
presented as mean ± SEM (n = 3 mice/group). (B). Intracellular Arg-1 expression in CD11b
+
 
lung leukocytes. After cell surface staining, cells were stained with anti-Arg-1 purified antibody 
followed by fluorescent anti-IgG-FITC to analyze intracellular Arg-1 in CD11b
+
 cells by flow 
cytometry. Percentages of CD11b
+
Arg-1
+
 cells within CD45
+
 leukocytes are shown for lungs 
from control and treated mice. The data are presented as mean ± SEM (n = 3 mice/group). 
*p<0.05, **p<0.01 radiation compared to control or radiation + soy compared to radiation alone. 
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Flow cytometry analysis of intracellular Arg-1 in CD11b
+
 myeloid-derived supporessor cell 
subsets in lung tissue treated with radiation and soy isoflavones. To further interrogate the 
specific CD11b
+
 cell populations that are augmented by radiation and soy isoflavones treatment, 
we examined intracellular expression of Arg-1 in monocytic- and granulocytic-MDSC subsets by 
flow cytometry (Figure 3.4). Lung cell suspensions were immunostained using a 5-color 
fluorophore combination of antibodies directed against CD45, CD11b, Ly6C, Ly6G and 
intracellular Arg-1 from lungs treated with soy isoflavones, radiation or radiation + soy at 1 week 
after radiation, as detailed in Materials and Methods. CD11b
+
 myeloid subsets were gated based 
on their differential expression of Ly6C and Ly6G to analyze monocytic-MDSCs 
(CD11b
+
Ly6C
+
Ly6G
-
) and granulocytic-MDSCs (CD11b
+
Ly6C
-
Ly6G
+
) (Figure 3.4). 
In order to dissect the specific CD11b
+
 cells population responsible for Arg-1 expression 
in the lung, we analyzed Ly6C and Ly6G subsets (Figure 3.5A). CD11b
+
Ly6C
-
Ly6G
+
 
granulocytic-MDSCs highly express Arg-1 (~70% in control mice), while other CD11b
+
 Ly6C 
and Ly6G subpopulations minimally expressed Arg-1. Only about 1% of monocytic-MDSCs 
expressed Arg-1 across all treatment groups (data not shown). Radiation and/or soy isoflavones 
treatment did not affect the percentage of CD11b
+
Ly6C
-
Ly6G
+
 granulocytic-MDSC in the lung 
at 1 week post-radiation (Figure 3.5B). However, radiation significantly decreased the 
percentage of CD11b
+
Ly6C
-
Ly6G
+
Arg-1
+
 granulocytes in lungs (p=0.0050) compared to control 
(Figure 3.5C), while CD11b
+
Ly6C
-
Ly6G
+
 granulocytes from Rad+Soy mice had significantly 
more Arg-1
+
 cells (p=0.0032), compared to radiation alone, and these percentages were 
comparable to those of control lungs (Figure 3.5C).  
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Figure 3.4. Gating strategy for granulocytic and monocytic MDSC subsets in the lungs. 
Single-cell suspensions obtained from the lungs were analyzed. CD11b
+
 cells within CD45
+
 
leukocytes were gated (see Figure 3.2 for gating method). To further interrogate the specific 
CD11b
+
 cell populations that are being augmented by radiation and soy isoflavones treatment, 
we examined in monocytic- and granulocytic-MDSC subsets by flow cytometry. CD11b
+
 
myeloid subsets were gated based on differential expression of Ly6C and Ly6G to analyze 
monocytic-MDSCs (CD11b
+
Ly6C
+
Ly6G
-
) and granulocytic-MDSCs (CD11b
+
Ly6C
-
Ly6G
+
).  
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Figure 3.5. Intracellular flow cytometry analysis of Arg-1 expression in CD11b
+
Ly6C
-
Ly6G
+
 granulocytic-MDSCs at 1 week after radiation. (A). Analysis of CD11b
+
Ly6C
-
Ly6G
+
 
granulocytic MDSCs in lung. At 1 week after radiation, lungs from control (Con) mice, and mice 
treated with soy (Soy), radiation (Rad) or radiation + soy (R+S) were dissociated into single cell 
suspensions. Cells were stained with anti-CD45, anti-CD11b, anti-Ly6C, and anti-Ly6G 
fluorescent antibodies to analyze CD11b
+
 myeloid cells within CD45
+
 leukocyte populations by 
flow cytometry. (B) Percentages of CD11b
+
Ly6C
-
Ly6G
+
 granulocytic MDSCs within the 
CD11b
+
 gated cells are shown for lungs from control and treated mice. The data are presented as 
mean ± SEM (n = 3 mice/group). (C). Intracellular Arg-1 expression in CD11b
+
 lung leukocytes. 
After cell surface staining, cells were stained with anti-Arg-1 purified antibody followed by 
fluorescent anti-IgG-FITC to analyze intracellular Arg-1 in CD11b
+
 cells by flow cytometry. 
Percentages of CD11b
+
Arg-1
+
 cells within CD45
+
 leukocytes are shown for lungs from control 
and treated mice. The data are presented as mean ± SEM (n = 3 mice/group). **p<0.01 radiation 
compared to control or radiation + soy compared to radiation alone.  
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Effect of soy-mediated early immunosuppressive phenotype in irradiated tissue on 
subsequent radiation-induced pro-inflammatory cytokine levels in lung homogenates. We 
showed that soy isoflavones promote an immunosuppressive granulocytic-MDSC phenotype at 
an early time point after radiation, with increased CD11b
+
Ly6C
-
Ly6G
+
Arg-1
+
 cells in irradiated 
lungs with in mice receiving soy isoflavones treatment. To determine if early Arg-1 expression 
in granulocytic-MDSCs results in a later functional anti-inflammatory effect, we measured 
radiation-induced pro-inflammatory cytokine expression subsequent to the soy-mediated 
promotion of immunosuppressive MDSC phenotype observed at 1 week. Indeed, soy isoflavones 
treatment inhibited radiation-induced cytokine production in lung tissue at 4 weeks post-
irradiation (Figure 3.6). Inflammatory cytokines associated with radiation injury were 
significantly reduced by soy isoflavones supplementation, including IL-1β (p=0.0030), IL-6 
(p=0.0061), and TNF-α (p=.0057). Increased Arg-1 expression at an earlier time point (1wk 
post-radiation) may contribute to the attenuation of pro-inflammatory cytokine expression 
observed in lungs at a later time point (4wks post-radiation).   
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Figure 3.6. Supplementation with soy isoflavones inhibits radiation-induced cytokine 
production in lung tissue at 4 weeks post-radiation. Cytokine levels were measured by ELISA 
in lung homogenates obtained from mice at a time point of 4 weeks following irradiation. The 
data are presented as mean ± SEM (n = 4-9 mice/group). **p<0.01 radiation compared to control 
or radiation + soy compared to radiation alone.  
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DISCUSSION 
 
Radiation-induced pro-inflammatory cytokine expression in the lung plays an important 
role in promoting and perpetuating inflammation that contributes to the pathology of lung injury 
after thoracic radiation. Acute inflammation triggered after a single dose of radiation sets off a 
cascade of events that is akin to an aberrant wound healing response. We have reported in 
preclinical mouse models that supplementation with soy isoflavones to thoracic irradiation 
mitigates radiation-induced inflammatory cytokines, infiltration of inflammatory cells and 
fibrosis (36, 134, 135), but the immunosuppressive mediators of radioprotection remain unclear. 
In Chapter 2, we investigated the role of macrophages and neutrophils in the mitigation of 
radiation-induced inflammatory events by soy isoflavones in lung tissue. Our findings suggested 
that a radioprotective mechanism of soy isoflavones in lung involves the inhibition of infiltration 
and activation of macrophages and neutrophils in irradiated lungs. 
Additionally, soy isoflavones may also radioprotect 
 by promoting immunosuppressive phenotypes and anti-inflammatory molecular 
mediators after injury. Thus, radioprotection in lung tissue could also be achieved by the indirect 
suppression of radiation-induced pro-inflammatory cells and pathways. In this chapter, we 
demonstrated that soy isoflavones play a role in the promotion of an immunosuppressive 
phenotype in the lung at an early time point after a single dose of irradiation, and may 
downregulate damaging radiation-induced inflammation. 
We found that arginase-1, an enzyme with an important immunosuppressive and 
regulatory role (42), was decreased in lungs at 1 week post-irradiation, as confirmed by IHC and 
western blot. Soy isoflavones supplementation protected Arg-1 levels in irradiated lungs, similar 
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to that of control lungs. In control lungs, Arg-1
+
 cells are evenly distributed across alveolar septa 
while Arg-1
+
 cells were sparsely found in areas of thickened septa and staining was overall 
greatly reduced in lungs treated with radiation. Staining of lungs from mice receiving soy 
isoflavones in conjunction with radiation revealed a degree of Arg-1 positivity that was similar to 
control lungs. These data indicate that radiation caused the depletion of Arg-1
+
 cells that 
normally occur the lung, or reduced the expression of Arg-1 in cells lung tissue, while soy 
isoflavones protected from this radiation effect. These findings were confirmed by western blot 
analysis of Arg-1 expression in lung tissue lysates showing a decrease induced by radiation, 
which was inhibited by the addition of soy isoflavones. Decreased Arg-1 levels in the lung after 
radiation may allow for tissue damaging pro-inflammatory processes to proceed unhindered, and 
our data indicate that soy isoflavones may mediate radioprotection by promoting 
immunosuppression via Arg-1.  
To identify the specific Arg-1
+
 cell population affected by radiation and soy isoflavones, 
we performed flow cytometry studies to probe the myeloid compartment of the lungs, as these 
cells are known to produce arginase (161). Radiation and/or soy isoflavones treatment did not 
affect the percentage of CD11b
+
 cells in the lung at 1 week post-radiation, however radiation 
significantly decreased the percentage of Arg-1
+
 cells within the CD11b
+
 cellular compartment 
in lungs compared to control.  A subset of CD11b
+
 cells showed typical characteristics of 
myeloid-derived suppressor cells, with a CD11b
+
Ly6C
-
Ly6G
+ 
immunophenotype and high 
arginase-1 expression (155). This population of CD11b
+
Ly6C
-
Ly6G
+
 MDSCs are granulocytic in 
nature, given their high expression of Ly6G and lack of Ly6C. At 1 week post-radiation, we 
found that these granulocytic-MDSCs in irradiated lungs showed significantly less intracellular 
Arg-1 compared to control, while lungs from Rad+Soy mice revealed significantly increased 
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percentages of CD11b
+
Ly6C
-
Ly6G
+
Arg-1
+
 cells compared to radiation alone. These finding 
suggest that soy isoflavones supplementation in mice receiving a single dose of thoracic 
radiation promotes Arg-1 expression in a granulocytic subset of MDSCs in the lung at an early 
point after irradiation. 
In order to determine if this early promotion of Arg-1 in granulocytic MDSCs mediated 
by soy isoflavones results in downstream immunosuppression at a later time point, we measured 
the effect of soy isoflavones treatment on pro-inflammatory cytokines levels in lung 
homogenates at 4 weeks post-radiation. Inflammatory cytokines are implicated in radiation-
induced pneumonitis and fibrosis (30, 162). We found that soy isoflavones significantly reduced 
the levels of the radiation-induced pro-inflammatory cytokines IL-1β, IL-6, and TNF-α at 4 week 
post-radiation. These studies indicate that the early promotion of Arg-1
+
 granulocytic-MDSCs by 
soy isoflavones in irradiated lung may result in the later inhibition of radiation-induced 
inflammatory cytokine release. 
Arg-1 was shown to attenuate inflammatory cytokine expression in a rabbit model of 
atherosclerosis (163). Wang et. al. reported that upregulation of Arg-1 resulted in significantly 
decreased macrophage infiltration and inflammation in atherosclerotic plaques, corroborating our 
findings of soy radioprotection in lungs. In summary, our pre-clinical study in lung suggests that 
a radioprotective mechanism of soy isoflavones could involve the promotion of granulocytic 
myeloid-derived suppressor cells that express Arg-1 after radiation, resulting in subsequent 
downregulation of tissue damaging inflammation.   
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CHAPTER 4 
Molecular Mediators of Radioprotection of Lung Tissue by Soy Isoflavones 
 
ABSTRACT 
 
Radiation-induced lung injury results from a cascade of inflammatory processes leading 
to clinical pneumonitis and fibrosis. Our lab has previously reported that treatment with soy 
isoflavones mitigates inflammation and fibrosis but the mechanism of radioprotection was 
unclear. In this final chapter, we investigate molecular mediators of radiation-induced 
inflammation modulated by soy isoflavones that protect lung tissue from injury in naïve mice. 
BALB/c mice received a single 10 Gy thoracic irradiation with soy isoflavones given orally at 1 
mg/day, prior-to and continuously after radiation. Lungs were resected at different time points up 
to 18 weeks after radiation and processed for histology, western blot, and ELISA. E-cadherin, a 
cell adhesion molecule important airway epithelium barrier function, was assessed by IHC. Lung 
homogenates were processed to determine cytokine expression by ELISA and expression of NF-
κB p65 by western blot. At 4 weeks post-irradiation, E-cadherin positive staining was decreased 
in areas of thickened septa while considerably higher levels of E-cadherin were observed 
following radiation + soy treatment, compared to radiation-treated lungs. Soy isoflavones 
modulated radiation-induced Th1/M1 pro-inflammatory cytokines more so than Th2/M2 
cytokines. NF-κB p65 transcription factor subunit that plays a role in promoting inflammation 
was upregulated by radiation and decreased in lungs from mice treated with radiation and soy. 
These findings suggest that a mechanism of radioprotection by soy isoflavones involves the 
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regulation of radiation-induced molecular inflammatory events caused by the destruction of 
normal lung tissue.  
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INTRODUCTION 
 
Radiation-induced pneumonitis and fibrosis is initiated by an inflammatory response 
triggered by tissue and cell damage that results in the cyclical induction of pro-inflammatory 
cytokines and chemokines which recruit inflammatory immune cells in the lung tissue and drive 
RILI pathogenesis (23, 29, 30). In a pre-clinical lung cancer model, we showed that 
supplementation with a mixture of soy isoflavones given pre- and post-thoracic irradiation 
mitigated the vascular damage, inflammation and fibrosis caused by high dose radiation injury to 
lung tissue, suggesting that soy can alter the radiation-induced inflammatory response (36, 134). 
In chapters 2 and 3 of this dissertation, we demonstrate that soy isoflavones inhibit radiation-
induced macrophage and neutrophil infiltration and activation, while promoting 
immunosuppressive function of granulocytic MDSCs that are depleted in irradiated lungs. This 
chapter investigates the molecular mediators of inflammation modulated by soy isoflavones that 
protect lung tissue from radiation-induced injury in naïve mice. 
Thoracic radiation therapy can damage the lung epithelial barrier integrity by interrupting 
adherens junctions that bind cells together within this organ. E-cadherin is a cell-cell adhesion 
molecule critical for the maintenance of tight junctions between cells of the airway epithelium 
(48). Decreased E-cadherin expression in the lung would be indicative of a disrupted epithelial 
barrier, which can result in the recruitment of inflammatory cellular and molecular mediators and 
drive chronic inflammation. Thus, the effect of soy isoflavones on the expression of E-cadherin 
in irradiated lung tissue was investigated. 
Soy isoflavones have been shown to have anti-inflammatory properties in chronic 
inflammation and cardiovascular disease (164). Chacko et. al. demonstrated that anti-
77 
  
 
inflammatory mechanisms of soy isoflavones include modulation of leukocyte-endothelial cell 
interactions in an in vitro blood flow assay as well as pro-inflammatory cytokine inhibition that 
was dependent on activation of peroxisome proliferator-activated receptor (PPAR-γ) (107). 
Genistein has been shown to down-regulate cytokine-induced pro-inflammatory pathways in 
human brain microvascular endothelial cells (106). The microenvironment in which a cytokine is 
released contributes to the function of that particular cytokine. Therefore, the timing and context 
of the milieu into which a particular cytokine is released determines functional outcome. 
In chapters 2 and 3, we focused on cellular mediators of radioprotection by soy 
isoflavones in normal lung. In this final chapter, we further study the modulation of 
inflammatory response by soy isoflavones in irradiated lungs by investigating potential 
molecular mechanisms involved in soy radioprotection.  
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MATERIALS AND METHODS 
 
Mice 
Female BALB/c mice (Harlan, Indianapolis, IN) 5-6 weeks old, were housed and handled 
in animal facilities accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care. The animal protocol was approved by Wayne State University 
Institutional Animal Care and Use Committee.  
 
Soy isoflavones 
The soy isoflavone mixture G-4660 used is a pure extract of 98.16% isoflavones from 
soybeans consisting of 83.3% genistein, 14.6% daidzein and 0.26% glycitein (manufactured by 
Organic Technologies and obtained from the National Institutes of Health [NIH], Bethesda, 
MD). The soy isoflavone mixture was dissolved in DMSO and mixed with sesame seed oil at a 
1:20 ratio just prior to treatment to facilitate gavage and avoid irritation of the esophagus by 
DMSO (36, 134, 135). 
 
Lung irradiation 
Radiation was delivered to the thoracic cage comprising the whole lung. Three 
anesthetized mice, in jigs, were positioned under a 6.4 mm lead shield with 3 cut-outs in an 
aluminum frame mounted on the X-ray machine to permit selective irradiation of the lung in 3 
mice at a time, as previously described (134). The radiation dose to the lung and the scattered 
dose to areas of the mouse outside of the radiation field were carefully monitored. To minimize 
backscattering of radiation, the bottom of the aluminum frame that holds the jigs was hollowed 
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out and the backplate of the jig was thinned to 1.6mm thickness. Under these conditions and the 
lead shielding, the X ray dose to the shielded regions was reduced to 1% of the dose to the 
irradiated field. The dose rate was 101 cGy/min and half value layer was 2 mm Cu. Photon 
irradiation was performed at a dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens 
Medical Systems, Inc., Erlangen, Germany) operated at 250 kV, 15 mA with 1 mm copper 
filtration at a distance of 47.5 cm from the target. 
 
Experimental Design 
Mice were pre-treated with oral soy isoflavones each day for 3 days at a dose of 5mg/day 
(equivalent to 250mg/kg). Then, the lung was selectively irradiated with 10 Gy.  Soy treatment 
was continued on a daily basis for 5 more days at 5mg/day. Then mice were treated with a lower 
soy dose of 1mg/day (equivalent to 50mg/kg), given daily 5 days a week for up to 18 weeks. The 
rationale for giving a higher dose of soy isoflavones for pre-treatment and just after radiation is 
to optimize the effect of soy, based on previous studies (36, 140). At different time points, 
separate mice from each treatment group were either homogenized for ELISA, snap frozen for 
western blot, or mice were used to fix lungs in situ with formalin for histology studies as detailed 
below. 
 
Preparation of Lung Tissue Protein Lysates and Western Blot Analysis 
Mice were sacrificed at 12 and 18 weeks post-irradiation. Lungs were resected and snap 
frozen. To prepare lung tissue protein lysates, frozen lungs were thawed, weighed, and 
homogenized in 10% w/v of lysis buffer using a gentleMACS tissue dissociator (Miltenyi Biotec, 
Bergisch, Germany). The suspension was centrifuged at 4000 x g for 5 minutes at 4°C and the 
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protein extracts were frozen at -80°C until analysis. For western blot analysis, total lung protein 
extracts (50 µg) were loaded and separated on 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to Whatman membranes (GE Healthcare Life 
Sciences, Pittsburgh, PA). Membranes were incubated with anti-NF-κB p65 antibody 
(eBioscience, Sn Diego, CA; 1:200) overnight at 4°C. Membranes were washed and incubated 
with horseradish peroxidase-conjugated secondary antibody (Vector Labs, 1:2000) at room 
temperature for 1 hour. Immunoreactive protein bands were visualized by SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Waltham, MA) and captured on a digital 
imaging system (Fotodyne Inc., Hartland, WI). Membranes were re-probed with anti-β-actin Ab 
as a loading control.15 
 
Immunohistochemistry (IHC) 
Mice were sacrificed and lungs were intratracheally instilled with 10% buffered formalin 
and resected, embedded in paraffin, and sectioned. Sections were blocked with IHC Tek 
Antibody Diluent (IHC World, Woodstock, MD) then incubated with primary purified 
monoclonal antibodies directed against epithelial cadherin (E-cadherin) or peroxisome 
proliferator-activated receptor (PPAR-γ) (eBioscience, San Diego, CA) overnight at 4° C. Lung 
sections were then incubated with biotinylated secondary antibodies (Vector Labs, Burlingame, 
CA) at 1:300 for 1 hour at room temperature. Staining was amplified with the avidin-biotin 
system Vectastain ABC Reagent Kit (Vector Labs) and visualized with the Vector DAB 
Substrate Kit for peroxidase (Vector Labs). Sections were counterstained with IHC-Tek Mayer’s 
Hematoxylin (IHC World, Woodstock, MD) and mounted with Permount mounting media 
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(Electron Microscopy Sciences, Hatfield, PA). Arg-1 expression in lung tissue after radiation 
was evaluated on a Nikon E800 microscope (Nikon Inc., Melville, NY).  
 
Enzyme-linked immunosorbant assay (ELISA) 
Mice were sacrificed at various time points between 0-18 weeks post-irradiation. Lungs 
were resected and snap frozen. To prepare lung homogenates, frozen lungs were thawed, 
weighed, and homogenized in 10% w/v of phosphate buffered saline (PBS) with Complete 
Protease Inhibitor Cocktail Tablets (Roche Diagnostics, Indianapolis, IN) using a gentleMACS 
tissue dissociator (Miltenyi Biotec, San Diego, CA). The suspension was centrifuged at 4000 x g 
for 5 minutes at 4°C and the supernatant was frozen at -80°C. Lung homogenates were assayed 
IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-13, IL-15, IL-17A, TNF-α, TGF-β, IFN-γ, and CCL2 using 
the respective Ready-SET-GO ELISA kits (eBioscience, San Diego, CA) according to 
manufacturer’s instructions.  
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RESULTS 
 
Effect of radiation and soy isoflavones on E-cadherin levels in lung tissue. Radiation can 
compromise endothelial and epithelial cell barrier integrity by interrupting adherens junctions 
that bind cells together within tissues. E-cadherin is an adhesion molecule expressed on epithelial 
cells (48). We previously showed that radiation-induced cytokines were decreased by soy 
isoflavones at 4 weeks post-irradiation, and thus we aimed to determine whether radiation 
affected cell barrier integrity at this same time point. Lung tissue sections were obtained from 
control mice and mice treated with radiation or radiation + soy isoflavones at 4 weeks after 
radiation and stained by IHC with E-cadherin.  Staining of E-cadherin showed that radiation 
caused a pronounced loss in positive staining in areas of thickened septa (Figure 4.1). In contrast, 
following radiation + soy isoflavones treatment, considerably higher levels of positive staining 
for E-cadherin were observed, compared to radiation-treated lungs (Figure 4.1).  
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Figure 4.1. In situ detection of E-cadherin in lung tissue at 4 weeks after radiation ± soy 
isoflavones. Lungs tissue sections were obtained from control (Con) mice and mice treated with 
radiation (Rad) or radiation + soy (Rad+Soy) at 4 weeks after radiation. Sections were stained by 
IHC for E-cadherin to detect expression in situ. Staining of E-cadherin showed that radiation 
caused a pronounced decrease in positive staining in areas of thickened septa at 4 weeks after 
radiation. In contrast, following radiation + soy treatment, considerably higher levels of positive 
staining for E-cadherin were observed, compared to radiation-treated lungs. Secondary antibody 
alone is shown as a staining control. All magnifications are at 40x.  
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Effect of radiation and soy isoflavones on cytokine levels in lung tissue. The effect of soy 
isoflavones on the kinetics of molecular meditors of the immune system triggered by radiaiton 
were evaluated in lungs. Cytokine and chemokine levels following radiation were measured over 
time by ELISA in lung homogenates obtained mice. Pro-inflammatory cytokine levels associated 
with Th1/M1 immune responses were evaluated over time after a single dose of thoracic 
radiation (Figure 4.2). Soy isoflavones inhibited pro-inflammatory cytokines induced by 
radiation, including IL-1β, IL-6, TNF-α, and IFN-γ (Figure 4.2). Additionally, treatment with soy 
isoflavones increased IL-1β and IFN-γ at early time points of 4-24 hours post-radiation, which 
could play an anti-fibrotic role in the irradiated lung (Figure 4.2). There are minimal differences 
in the kinetics of cytokines and chemokine levels associated with Th2/M2 immune responses in 
lungs harvested from mice treated with radiation compared to radiation + soy (Figure 4.3).  
Cytokine and chemokine levels in lungs from mice receiving daily soy isoflavones 
treatment or age matched controls revealed that, in general, soy isoflavones alone did not alter 
the cytokine or chemokine profile (Figure 4.4). This finding implies that soy isoflavones tend to 
modulate the immune system once an inflammatory insult has triggered the activation of 
pathways assoaciated with inflammation in cells and tissues.  
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Figure 4.2. Effect of soy isoflavones on the kinetics of Th1/M1 anti-inflammatory cytokine 
profile in irradiated lung tissue. Cytokine and chemokine levels associated with Th1/M1 
immune responses following radiation were measured over time by ELISA in lung homogenates 
obtained from mice.   
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Figure 4.3. Effect of soy isoflavones on the kinetics of Th2/M2 anti-inflammatory cytokine 
profile in irradiated lung tissue. Cytokine levels associated with Th2/M2 immune responses 
following radiation were measured over time by ELISA in lung homogenates obtained from 
mice. ND = not detectable.  
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Figure 4.4. Effect of soy isoflavones treatment on homeostatic cytokine profile in lung 
tissue. Cytokine and chemokine levels associated with Th1/M1 or Th2/M2 immune responses 
were measured over time by ELISA in lung homogenates obtained mice receiving daily soy 
isoflavones treatment or age matched controls. In general, soy isoflavones alone did not alter the 
cytokine or chemokine profile. 
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Effect of radiation and soy isoflavones on PPAR-γ in lung tissue. PPAR-γ plays a role in M2 
macrophage differentiation and activation (165). Expression of PPAR-γ in whole lung tissue as 
determined by western blot was increased after in both radiation-treated and radiation + soy-
treated lungs (Figure 4.5A). To further evaluate the effect of soy isoflavones on the radiation-
induced increase of PPAR- γ in lungs, tissue sections were obtained from control mice and mice 
treated with radiation or radiation + soy isoflavones at 18 weeks after radiation and stained with 
PPAR- γ. Interestingly, soy isoflavones altered cellular localization of PPAR-γ in alveolar 
macrophages at 18 weeks post-radiation. Alveolar macrophages showed cytoplasmic localization 
of PPAR-γ following radiation, in contrast to nuclear localization following supplementation 
with soy isoflavones (Figure 4.5B). Radiation caused a marked increase in PPAR-γ+ 
macrophages in thickened alveolar septa areas and spaces. Numerous alveolar macrophages 
showing the morphology of activated macrophages were particularly enlarged with abundant 
positive cytoplasmic staining compared to small macrophages in control lungs (arrows). The 
density of PPAR-γ+ macrophages was much lower in radiation + soy treated lungs at 18 weeks 
after radiation compared to radiation–treated lungs. Alveolar macrophages were also smaller, 
resembling those of control lungs and PPAR-γ positivity was more prominent in the nucleus 
rather than the cytoplasm, as compared to radiation–treated lungs.  
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Figure 4.5. Soy isoflavones alter cellular localization of PPAR-γ in alveolar macrophages at 
18 weeks post-radiation. (A). Western blot analysis of PPAR-γ on whole tissue lysates obtained 
from lungs showed an increase induced by radiation, including in irradiate lungs treated with soy 
isoflavones. Band intensities were quantified using ImageJ (NIH) densitometry analysis. (B). 
Lung tissue sections were obtained from control (Con) mice and mice treated with radiation 
(Rad) or radiation + soy (Rad+Soy) at 18 weeks after radiation. Lung sections were stained by 
IHC for PPAR-γ. Arrows indicate intense cytoplasmic PPAR-γ staining of alveolar 
macrophages. Radiation caused a marked increase in PPAR-γ+ macrophages in thickened areas 
of septa and in alveolar spaces. Numerous alveolar macrophages showing the morphology of 
activated macrophages were particularly enlarged with abundant positive cytoplasmic staining 
compared to small macrophages in control lungs (arrows). The density of PPAR-γ+ macrophages 
was much lower in radiation + soy treated lungs at 18 weeks after radiation compared to 
radiation–treated lungs. Alveolar macrophages were also smaller, resembling those of control 
lungs and PPAR-γ positivity was more prominent in the nucleus compared to radiation–treated 
lungs.  
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Effect of radiation and soy isoflavones on NF-κB in lung tissue. NF-κB promotes M1 
macrophage pro-inflammatory gene expression (166), and we have reported that radiation 
upregulates that constitutively active NF-κB is in prostate cancer cells (167). Western blot 
analysis of normal lung tissue obtained from mice treated with radiation and/or soy isoflavones 
revealed that NF-κB levels were increased by radiation and was inhibited by the addition of soy 
isoflavones at 12 weeks (Figure 4.6A) and 18 weeks (Figure 4.6B) post-radiation.   
91 
  
 
 
Figure 4.6. Soy isoflavones inhibit radiation-induced increase of NF-κB p65 subunit levels 
in lung tissue. Lungs tissue sections were obtained from control (Con) mice and mice treated 
with radiation (Rad) or radiation + soy (Rad+Soy) at 12 and 18 weeks after radiation. (A). 
Western blot analysis of NF-κB p65 on whole tissue lysates obtained from lungs at 12 weeks 
post-radiation showed an increase induced by radiation, which was inhibited by the addition of 
soy isoflavones. (B). An increase in NF-κB p65 was also observed at 18 weeks post-radiation, 
and an even more dramatic decrease in NF-κB p65 levels was detected in the lung at this later 
time point with the addition of soy isoflavones. Band intensities were quantified using ImageJ 
(NIH) densitometry analysis.  
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DISCUSSION 
 
Radiation can compromise endothelial and epithelial cell barrier integrity by interrupting 
adherens junctions that bind cells together within tissues. E-cadherin is a cell-cell adhesion 
molecule expressed on epithelial cells (48). Normal expression of E-cadherin is critical for the 
maintenance of tight junctions between epithelial cells and for maintenance of normal barrier 
function of airway epithelium. A reduction in the lung expression of E-cadherin is indicative of a 
damaged, disrupted epithelial barrier that can drive recruitment of inflammatory cells and 
promote a cascade of damage-associated molecular events and chronic inflammation. At 4 weeks 
post-irradiation, we found a pronounced loss in E-cadherin in areas of thickened septa by IHC. In 
contrast, following radiation + soy treatment, considerably higher levels of positive staining for 
E-cadherin were observed, compared to radiation-treated lungs. These data suggest that soy 
isoflavones maintain the cell-cell junctions important for proper tissue integrity in normal lung 
that are damaged by thoracic irradiation. 
Cytokine levels in lung homogenates of irradiated mice increase by 3-6 hours after 
radiation in correlation with levels measured in serum (162). The microenvironment in which a 
cytokine is released contributes to the function of that particular cytokine. Therefore, the timing 
and context of the milieu that a particular cytokine is released in determines functional outcome. 
The cytokine TGF-β is a canonical cytokine involved in driving fibrosis (168), whereas the 
cytokines IL-1β, IFN-γ, and TNF-α can play an anti-fibrotic role (169, 170). Interestingly, our 
model did not reveal a radiation-induced increase in TGF-β after radiation, even at a late time 
point of 18 week post-radiation, indicating that TGF-β may not play a pivotal role in RILI and 
fibrosis in our model. 
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 Nuclear factor κB (NF-κB) activation is a molecular common denominator between 
inflammation and cancer (108). This transcription factor is constitutively active in a large 
number of cancers and is critical for tumor cell survival. Our lab has previously shown that soy 
isoflavones target critical survival pathways that are upregulated or constitutively activated in 
cancer cells, including NF-κB, which are responsible for the transcription (109). In contrast, 
normal cells do not constitutively express NF-κB, and activation of this transcription factor is 
important for the expression of pro-inflammatory gene programs. We confirmed in vivo in naïve 
mice that soy isoflavones inhibited radiation-induced NF-κB increase in the lung at 12 and 18 
weeks post-irradiation. NF-κB promotes M1 macrophage pro-inflammatory gene expression 
(166). Peroxisomal proliferator-activated receptors (PPAR-α, β, δ, and γ) are ligand-activated 
transcription factors that heterodimerize with retinoid X receptor (RXR) to results gene 
expression (171). Promoting PPAR-γ activation by its cognate ligands have been shown to 
mitigate lung injury and fibrosis (172, 173). Soy isoflavones, in particular genistein, are known 
PPAR-γ ligands (174). PPAR-γ can influence the downregulation of pro-inflammatory mediators 
via trans-repression of NF-κB (175). Soy isoflavones may promote anti-inflammatory gene 
expression programs in the lung after thoracic radiation by interacting with PPAR-γ and 
downregulation of NF-κB. 
  In summary, our pre-clinical study in lung suggests that a radioprotective mechanism of 
soy isoflavones could involve the promotion of intact epithelial and endothelial tight junctions 
that are damaged after radiation via E-cadherin, resulting in subsequent downregulation of tissue 
damaging inflammation. Additionally, soy isoflavones may downregulate pro-inflammatory gene 
programs and cytokine expression upregulated by radiation-induced increases of NF-κB in 
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normal tissue, while promoting anti-inflammatory or repair pathways via the interaction of soy 
isoflavones with PPAR-γ.  
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GENERAL CONCLUSIONS 
  
 Chemoradiotherapy is currently the standard of care for unresectable locally advanced 
non-small cell lung carcinoma (NSCLC). However, the treatment success for this patient 
population has been severely constrained by post-therapy toxicity, presenting as pneumonitis and 
later fibrosis (176, 177). Conventional fractionated radiotherapy is associated with normal tissue 
side effects and poor quality of life (22).  Hypofractionated radiotherapy is an emerging modality 
for early-stage lung cancer, which can utilize a high radiation dose per fraction over a relatively 
short time period to improve effectiveness of tumor destruction and increase convenience by 
reducing the number of visits for therapy (178-180). However, high intensity radiotherapy can 
also be associated with greater damage to lung tissue, emphasizing the need to develop 
complementary approaches to alleviate radiation-induced injury to normal lung structures and 
function (60). 
Our pre-clinical murine studies (36, 134, 135) have already revealed that oral 
administration of a mixture of the soy isoflavones genistein, daidzein, and glycitein can enhance 
lung tumor eradication and simultaneously protect normal lung from radiation injury. While the 
anti-oxidant and disease preventative effects of a soy-rich diet have been investigated, prior to 
this dissertation project an immune-mediated mechanism of radioprotection by soy isoflavones 
in normal tissues remained to be elucidated. 
This dissertation has focused on investigating mechanisms of radioprotection mediated 
by soy isoflavones in normal lung tissue by dissecting the effect of soy supplementation on the 
radiation-induced inflammatory responses and immunosuppressive and repair pathways in 
irradiated lungs. Radiation therapy triggers a potent inflammatory response is a key contributor 
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to the tissue-damaging pathology of RILI. Our preclinical studies in lung cancer models and 
naïve mice indicate that soy isoflavones inhibit this inflammatory process or even promote tissue 
repair.  
In summary, our pre-clinical studies in lung suggest that a radioprotective mechanism of 
soy isoflavones likely involves both the inhibition of infiltration and activation of macrophages 
and neutrophils in irradiated lungs as well as the promotion of immunosuppressive myeloid-
derived suppressor cells (Figure 5). Soy isoflavones inhibited the radiation-induced infiltration 
and activation of macrophages and neutrophils in the lung, and polarized lung macrophages from 
M1 to M2 macrophage phenotype. Soy inhibited alveolar macrophage activation in 
bronchoalveolar spaces induced by radiation and had a protective effect on regulatory interstitial 
macrophages that could participate in maintaining lung homeostasis and control inflammation 
and tissue damage. We also show that treatment with soy isoflavones downregulates pro-
inflammatory gene programs and cytokine expression that are upregulated by radiation-induced 
increases of NF-κB in normal tissue, and may upregulating anti-inflammatory pathways via the 
interaction of isoflavones with PPAR-γ. Furthermore, soy isoflavones also promoted intact 
epithelial and endothelial tight junctions via E-cadherin that are damaged after radiation and 
granulocytic myeloid-derived suppressor cells that express Arg-1 after radiation, resulting in 
subsequent dampening of tissue damaging inflammation. These findings serve as potential 
mechanisms of soy-mediated radioprotection in normal lung, contributing to the resolution of 
radiation-induced acute and chronic inflammation that lead to pneumonitis and fibrosis.  
The clinical goal is to improve the therapeutic ratio of high-dose radiation therapy on the 
tumor target and reduce the radiation dose-limiting toxicity of radiation therapy to the normal 
lung. These findings suggest that soy isoflavones used as a complementary intervention to 
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radiotherapy for lung cancer could potentially reduce lung toxicity and provide improved 
therapeutic benefit to patients.   
98 
  
 
 
Figure 5. General conclusions and overall hypothesis. A single dose of thoracic irradiation 
triggers inflammatory responses in the lung that include increased NF-κB and pro-inflammatory 
cytokine production, as well as increases in the infiltration and activation of macrophages and 
neutrophils. Our findings suggest that soy can inhibit the infiltration and activation of 
macrophages and neutrophils induced by radiation in bronchoalveolar spaces and the lung 
parenchyma. Radiation induced a pro-inflammatory M1 macrophage phenotype in lungs, while 
mice receiving soy isoflavones and radiation switched to an anti-inflammatory M2 macrophage 
subtype. Soy isoflavones inhibited the radiation-induced upregulation of NF-κB and pro-
inflammatory cytokine release in the lung. Soy isoflavones also had a protective effect on 
regulatory interstitial macrophages (IM) after irradiation and Arg-1
+
 granulocytic MDSCs, while 
inhibiting alveolar macrophage (AM) activation induced by radiation. These data indicate that a 
mechanism of radioprotection by soy isoflavones in normal lung includes the modulation of 
innate immune cellular and molecular mediators of the inflammatory response induced by 
radiation.  
99 
  
 
REFERENCES 
 
1. Keane MP, Belperio JA, Henson PM, Strieter RM. 2005. Inflammation, injury, and 
repair, p. 449-490. In Murray JF, Nadel JA, Mason RJ, Broaddus VC (ed.), Textbook of 
respiratory medicine, 4th ed. Elsevier Saunders, Philadelphia, PA. 
2. Effros RM. 2006. Anatomy, development, and physiology of the lungs. GI Motility 
online. 
3. Tschernig T, Pabst R. 2009. What is the clinical relevance of different lung 
compartments? BMC Pulm Med 9:39. 
4. Martin TR, Frevert CW. 2005. Innate immunity in the lungs. Proc Am Thorac Soc 
2:403-411. 
5. Hussain AN. 2006. Immune system of the lungs, p. 366-368, Pathologic Basis of 
Disease. 
6. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, Deswarte K, 
Malissen B, Hammad H, Lambrecht BN. 2013. Alveolar macrophages develop from 
fetal monocytes that differentiate into long-lived cells in the first week of life via GM-
CSF. J Exp Med 210:1977-1992. 
7. Lambrecht BN. 2006. Alveolar macrophage in the driver's seat. Immunity 24:366-368. 
8. Holt PG. 1978. Inhibitory activity of unstimulated alveolar macrophages on T-
lymphocyte blastogenic response. Am Rev Respir Dis 118:791-793. 
9. Roberts LM, Ledvina HE, Tuladhar S, Rana D, Steele SP, Sempowski GD, 
Frelinger JA. 2015. Depletion of alveolar macrophages in CD11c diphtheria toxin 
receptor mice produces an inflammatory response. Immun Inflamm Dis 3:71-81. 
100 
  
 
10. Kruger P, Saffarzadeh M, Weber AN, Rieber N, Radsak M, von Bernuth H, 
Benarafa C, Roos D, Skokowa J, Hartl D. 2015. Neutrophils: Between host defence, 
immune modulation, and tissue injury. PLoS Pathog 11:e1004651. 
11. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. 2010. 
Neutrophil kinetics in health and disease. Trends Immunol 31:318-324. 
12. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N, 
Frodin JE, Jarhult J, Lamnevik G, Lindholm C, Littbrand B, Norlund A, Nylen U, 
Rosen M, Svensson H, Moller TR. 2003. The Swedish Council on Technology 
Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer 
including a prospective survey of radiotherapy practice in Sweden 2001--summary and 
conclusions. Acta Oncol 42:357-365. 
13. Coggle JE, Lambert BE, Moores SR. 1986. Radiation effects in the lung. Environ 
Health Perspect 70:261-291. 
14. Stone HB, Coleman CN, Anscher MS, McBride WH. 2003. Effects of radiation on 
normal tissue: consequences and mechanisms. Lancet Oncol 4:529-536. 
15. Rubin P, Casarett GW. 1968. Clinical radiation pathology as applied to curative 
radiotherapy. Cancer 22:767-778. 
16. Dörr W. 2009. Pathogenesis of normal-tissue side-effects, p. 169-190. In Joiner M, van 
der Kogel A (ed.), Basic Clinical Radiobiology Fourth Edition. CRC Press. 
17. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet 
NG. 2009. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by 
genotype. Nat Rev Cancer 9:134-142. 
101 
  
 
18. van Meerbeeck JP, Meersschout S, De Pauw R, Madani I, De Neve W. 2008. Modern 
radiotherapy as part of combined modality treatment in locally advanced non-small cell 
lung cancer: present status and future prospects. Oncologist 13:700-708. 
19. Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, Purdy JA, 
Michalski JM, Gore E, Choy H. 2010. Primary analysis of the phase II component of a 
phase I/II dose intensification study using three-dimensional conformal radiation therapy 
and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: 
RTOG 0117. J Clin Oncol 28:2475-2480. 
20. Kelsey CR, Rosenstein BS, Marks LB. 2012. Predicting toxicity from radiation 
therapy--it's genetic, right? Cancer 118:3450-3454. 
21. Schallenkamp JM, Miller RC, Brinkmann DH, Foote T, Garces YI. 2007. Incidence 
of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat 
Oncol Biol Phys 67:410-416. 
22. Williams JP, Johnston CJ, Finkelstein JN. 2010. Treatment for radiation-induced 
pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug 
Targets 11:1386-1394. 
23. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, 
Turrisi A, Lichter A, Fraass B, Eisbruch A, Lawrence TS, Ten Haken RK. 2006. 
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell 
lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat 
Oncol Biol Phys 65:1075-1086. 
102 
  
 
24. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. 
2000. Factors predicting severe radiation pneumonitis in patients receiving definitive 
chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48:89-94. 
25. McDonald S, Rubin P, Phillips TL, Marks LB. 1995. Injury to the lung from cancer 
therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J 
Radiat Oncol Biol Phys 31:1187-1203. 
26. Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK. 2004. 
Effects of radiation therapy on the lung: radiologic appearances and differential 
diagnosis. Radiographics 24:985-997; discussion 998. 
27. Morgan GW, Breit SN. 1995. Radiation and the lung: a reevaluation of the mechanisms 
mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31:361-369. 
28. Ghafoori P, Marks LB, Vujaskovic Z, Kelsey CR. 2008. Radiation-induced lung 
injury. Assessment, management, and prevention. Oncology 22:37-47; discussion 52-33. 
29. Hill RP. 2005. Radiation effects on the respiratory system. The British Journal of 
Radiology Supplement_27:75-81. 
30. Bentzen SM. 2006. Preventing or reducing late side effects of radiation therapy: 
radiobiology meets molecular pathology. Nat Rev Cancer 6:702-713. 
31. Strieter RM. 2008. What differentiates normal lung repair and fibrosis? Inflammation, 
resolution of repair, and fibrosis. Proc Am Thorac Soc 5:305-310. 
32. Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN. 1995. A perpetual 
cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol 
Phys 33:99-109. 
103 
  
 
33. Burger A, Loffler H, Bamberg M, Rodemann HP. 1998. Molecular and cellular basis 
of radiation fibrosis. Int J Radiat Biol 73:401-408. 
34. Rubin P, Finkelstein J, Shapiro D. 1992. Molecular biology mechanisms in the 
radiation induction of pulmonary injury syndromes: interrelationship between the 
alveolar macrophage and the septal fibroblast. Int J Radiat Oncol Biol Phys 24:93-101. 
35. Tsoutsou PG, Koukourakis MI. 2006. Radiation pneumonitis and fibrosis: mechanisms 
underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol 
Phys 66:1281-1293. 
36. Hillman GG, Singh-Gupta V, Runyan L, Yunker CK, Rakowski JT, Sarkar FH, 
Miller S, Gadgeel SM, Sethi S, Joiner MC, Konski AA. 2011. Soy isoflavones 
radiosensitize lung cancer while mitigating normal tissue injury. Radiother Oncol 
101:329-336. 
37. Franke-Ullmann G, Pfortner C, Walter P, Steinmuller C, Lohmann-Matthes ML, 
Kobzik L. 1996. Characterization of murine lung interstitial macrophages in comparison 
with alveolar macrophages in vitro. J Immunol 157:3097-3104. 
38. Laskin DL, Weinberger B, Laskin JD. 2001. Functional heterogeneity in liver and lung 
macrophages. J Leukoc Biol 70:163-170. 
39. Franko AJ, Sharplin J. 1994. Development of fibrosis after lung irradiation in relation 
to inflammation and lung function in a mouse strain prone to fibrosis. Radiat Res 
140:347-355. 
40. Ricardo SD, van Goor H, Eddy AA. 2008. Macrophage diversity in renal injury and 
repair. J Clin Invest 118:3522-3530. 
104 
  
 
41. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. 
Nat Rev Immunol 8:958-969. 
42. Barbul A. 2008. Proline precursors to sustain Mammalian collagen synthesis. J Nutr 
138:2021S-2024S. 
43. Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, Norwood C, 
Wang E, Marincola FM, Stroncek DF. 2007. Gene expression profiling of cutaneous 
wound healing. J Transl Med 5:11. 
44. Grommes J, Soehnlein O. 2011. Contribution of neutrophils to acute lung injury. Mol 
Med 17:293-307. 
45. Bradley PP, Priebat DA, Christensen RD, Rothstein G. 1982. Measurement of 
cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J 
Invest Dermatol 78:206-209. 
46. Haston CK, Begin M, Dorion G, Cory SM. 2007. Distinct loci influence radiation-
induced alveolitis from fibrosing alveolitis in the mouse. Cancer research 67:10796-
10803. 
47. Sener G, Jahovic N, Tosun O, Atasoy BM, Yegen BC. 2003. Melatonin ameliorates 
ionizing radiation-induced oxidative organ damage in rats. Life Sci 74:563-572. 
48. Takeichi M. 1991. Cadherin cell adhesion receptors as a morphogenetic regulator. 
Science 251:1451-1455. 
49. Kaur P, Asea A. 2012. Radiation-induced effects and the immune system in cancer. 
Front Oncol 2:191. 
50. Eckes B, Zigrino P, Kessler D, Holtkotter O, Shephard P, Mauch C, Krieg T. 2000. 
Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 19:325-332. 
105 
  
 
51. Thannickal VJ, Toews GB, White ES, Lynch JP, 3rd, Martinez FJ. 2004. 
Mechanisms of pulmonary fibrosis. Annu Rev Med 55:395-417. 
52. Thompson HG, Mih JD, Krasieva TB, Tromberg BJ, George SC. 2006. Epithelial-
derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. 
Am J Physiol Lung Cell Mol Physiol 291:L1277-1285. 
53. Khalil N, Bereznay O, Sporn M, Greenberg AH. 1989. Macrophage production of 
transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary 
inflammation. J Exp Med 170:727-737. 
54. Penn JW, Grobbelaar AO, Rolfe KJ. 2012. The role of the TGF-beta family in wound 
healing, burns and scarring: a review. Int J Burns Trauma 2:18-28. 
55. Vujaskovic Z, Groen HJ. 2000. TGF-beta, radiation-induced pulmonary injury and lung 
cancer. Int J Radiat Biol 76:511-516. 
56. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, Jirtle RL. 
1998. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. 
Int J Radiat Oncol Biol Phys 41:1029-1035. 
57. Fu XL, Huang H, Bentel G, Clough R, Jirtle RL, Kong FM, Marks LB, Anscher 
MS. 2001. Predicting the risk of symptomatic radiation-induced lung injury using both 
the physical and biologic parameters V(30) and transforming growth factor beta. Int J 
Radiat Oncol Biol Phys 50:899-908. 
58. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, 
Lebesque JV. 2004. Significance of plasma transforming growth factor-beta levels in 
radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58:1378-1387. 
106 
  
 
59. Brizel DM. 2007. Pharmacologic approaches to radiation protection. J Clin Oncol 
25:4084-4089. 
60. Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B, Coleman 
CN. 2012. Normal tissue protection for improving radiotherapy: Where are the Gaps? 
Transl Cancer Res 1:35-48. 
61. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. 2010. 
Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 
15:360-371. 
62. Kwok E, Chan CK. 1998. Corticosteroids and azathioprine do not prevent radiation-
induced lung injury. Can Respir J 5:211-214. 
63. Ward HE, Kemsley L, Davies L, Holecek M, Berend N. 1993. The effect of steroids 
on radiation-induced lung disease in the rat. Radiat Res 136:22-28. 
64. Abratt RP, Morgan GW, Silvestri G, Willcox P. 2004. Pulmonary complications of 
radiation therapy. Clin Chest Med 25:167-177. 
65. Bonnans C, Chou J, Werb Z. 2014. Remodelling the extracellular matrix in 
development and disease. Nat Rev Mol Cell Biol 15:786-801. 
66. Okunieff P, Augustine E, Hicks JE, Cornelison TL, Altemus RM, Naydich BG, Ding 
I, Huser AK, Abraham EH, Smith JJ, Coleman N, Gerber LH. 2004. Pentoxifylline 
in the treatment of radiation-induced fibrosis. J Clin Oncol 22:2207-2213. 
67. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grunwald C, 
Knobler R, Schwarz A, Luger TA, Schwarz T. 1994. Pentoxifylline in vivo down-
regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human 
peripheral blood mononuclear cells. Immunology 83:262-267. 
107 
  
 
68. Oliveira-Junior IS, Pinheiro BV, Silva ID, Salomao R, Zollner RL, Beppu OS. 2003. 
Pentoxifylline decreases tumor necrosis factor and interleukin-1 during high tidal 
volume. Braz J Med Biol Res 36:1349-1357. 
69. Rube CE, Wilfert F, Uthe D, Schmid KW, Knoop R, Willich N, Schuck A, Rube C. 
2002. Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) 
expression in the lung tissue by pentoxifylline. Radiother Oncol 64:177-187. 
70. Ozturk B, Egehan I, Atavci S, Kitapci M. 2004. Pentoxifylline in prevention of 
radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind 
randomized trial. Int J Radiat Oncol Biol Phys 58:213-219. 
71. Sweitzer NK. 2003. Cardiology patient page. What is an angiotensin converting enzyme 
inhibitor? Circulation 108:e16-18. 
72. Ward WF, Molteni A, Ts'ao CH. 1989. Radiation-induced endothelial dysfunction and 
fibrosis in rat lung: modification by the angiotensin converting enzyme inhibitor 
CL242817. Radiat Res 117:342-350. 
73. Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. 2012. Decreased risk of radiation 
pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors 
and thoracic radiation therapy. Int J Radiat Oncol Biol Phys 84:238-243. 
74. Yuhas JM, Storer JB. 1969. Differential chemoprotection of normal and malignant 
tissues. J Natl Cancer Inst 42:331-335. 
75. Kouvaris JR, Kouloulias VE, Vlahos LJ. 2007. Amifostine: the first selective-target 
and broad-spectrum radioprotector. Oncologist 12:738-747. 
76. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, 
Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst 
108 
  
 
R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. 2002. Randomized phase III study 
of chemoradiation with or without amifostine for patients with favorable performance 
status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin 
Radiat Oncol 12:46-49. 
77. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, 
Zhang J, Russell L, Oster W, Sauer R. 2000. Phase III randomized trial of amifostine 
as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345. 
78. Sanchez-Chino X, Jimenez-Martinez C, Davila-Ortiz G, Alvarez-Gonzalez I, 
Madrigal-Bujaidar E. 2015. Nutrient and nonnutrient components of legumes, and its 
chemopreventive activity: a review. Nutrition and cancer 67:401-410. 
79. Barnes S. 2010. The biochemistry, chemistry and physiology of the isoflavones in 
soybeans and their food products. Lymphat Res Biol 8:89-98. 
80. Kang J, Badger TM, Ronis MJ, Wu X. 2010. Non-isoflavone phytochemicals in soy 
and their health effects. J Agric Food Chem 58:8119-8133. 
81. Dakora FD, Joseph CM, Phillips DA. 1993. Alfalfa (Medicago sativa L.) Root 
Exudates Contain Isoflavonoids in the Presence of Rhizobium meliloti. Plant Physiol 
101:819-824. 
82. Rolfe BG. 1988. Flavones and isoflavones as inducing substances of legume nodulation. 
BioFactors (Oxford) 1:3-10. 
83. Markiewicz L, Garey J, Adlercreutz H, Gurpide E. 1993. In vitro bioassays of non-
steroidal phytoestrogens. J Steroid Biochem Mol Biol 45:399-405. 
109 
  
 
84. Branham WS, Dial SL, Moland CL, Hass BS, Blair RM, Fang H, Shi L, Tong W, 
Perkins RG, Sheehan DM. 2002. Phytoestrogens and mycoestrogens bind to the rat 
uterine estrogen receptor. J Nutr 132:658-664. 
85. Messina M. 2010. Isoflavones, p. 439-449. In Coates PM, Betz J, Blackman M, Cragg G, 
Levine M, Moss J, White J (ed.), Encyclopedia of Dietary Supplemets. Informa 
Healthcare, New York, NY. 
86. Shanle EK, Xu W. 2011. Endocrine disrupting chemicals targeting estrogen receptor 
signaling: identification and mechanisms of action. Chem Res Toxicol 24:6-19. 
87. Omoni AO, Aluko RE. 2005. Soybean foods and their benefits: potential mechanisms of 
action. Nutr Rev 63:272-283. 
88. Dakora FD, Phillips DA. 1996. Diverse functions of isoflavonoids in legumes transcend 
anti-microbial definitions of phytoalexins. Physiological and Molecular Plant Pathology 
49:1-20. 
89. Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E. 2010. Differential effects of whole 
soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med 
(Maywood) 235:90-97. 
90. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar 
FH, Hillman GG. 2007. Soy isoflavones enhance radiotherapy in a metastatic prostate 
cancer model. Int J Cancer 120:2491-2498. 
91. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. 1998. Nutritional and 
socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J 
Natl Cancer Inst 90:1637-1647. 
110 
  
 
92. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van 
der Burg B, Gustafsson JA. 1998. Interaction of estrogenic chemicals and 
phytoestrogens with estrogen receptor beta. Endocrinology 139:4252-4263. 
93. Banerjee S, Li Y, Wang Z, Sarkar FH. 2008. Multi-targeted therapy of cancer by 
genistein. Cancer Letters 269:226-242. 
94. Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ. 2008. 
Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer 
Prostatic Dis 11:6-12. 
95. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. 2003. Soy and 
isoflavone consumption in relation to prostate cancer risk in China. Cancer epidemiology, 
biomarkers & prevention : a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive Oncology 12:665-668. 
96. Holzbeierlein JM, McIntosh J, Thrasher JB. 2005. The role of soy phytoestrogens in 
prostate cancer. Curr Opin Urol 15:17-22. 
97. Kurosu M. 2011. Biologically Active Molecules from Soybeans. In El-Shemy H (ed.), 
Biologically Active Molecules from Soybeans, Soybean and Health. 
98. Day JK, Bauer AM, DesBordes C, Zhuang Y, Kim BE, Newton LG, Nehra V, 
Forsee KM, MacDonald RS, Besch-Williford C, Huang TH, Lubahn DB. 2002. 
Genistein alters methylation patterns in mice. J Nutr 132:2419S-2423S. 
99. Sit KH, Bay BH, Wong KP. 1993. Effect of genistein, a tyrosine-specific protein kinase 
inhibitor, on cell rounding by pH upshifting. In Vitro Cell Dev Biol Anim 29A:395-402. 
100. Coward L, Smith M, Kirk M, Barnes S. 1998. Chemical modification of isoflavones in 
soyfoods during cooking and processing. Am J Clin Nutr 68:1486S-1491S. 
111 
  
 
101. Andres S, Abraham K, Appel KE, Lampen A. 2011. Risks and benefits of dietary 
isoflavones for cancer. Crit Rev Toxicol 41:463-506. 
102. Day AJ, DuPont MS, Ridley S, Rhodes M, Rhodes MJ, Morgan MR, Williamson G. 
1998. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine 
and liver beta-glucosidase activity. FEBS Lett 436:71-75. 
103. Hendrich S. 2002. Bioavailability of isoflavones. J Chromatogr B Analyt Technol 
Biomed Life Sci 777:203-210. 
104. Cooke PS, Selvaraj V, Yellayi S. 2006. Genistein, estrogen receptors, and the acquired 
immune response. J Nutr 136:704-708. 
105. Cui S, Wienhoefer N, Bilitewski U. 2014. Genistein induces morphology change and 
G2/M cell cycle arrest by inducing p38 MAPK activation in macrophages. Int 
Immunopharmacol 18:142-150. 
106. Lee YW, Lee WH. 2008. Protective effects of genistein on proinflammatory pathways in 
human brain microvascular endothelial cells. J Nutr Biochem 19:819-825. 
107. Chacko BK, Chandler RT, Mundhekar A, Khoo N, Pruitt HM, Kucik DF, Parks 
DA, Kevil CG, Barnes S, Patel RP. 2005. Revealing anti-inflammatory mechanisms of 
soy isoflavones by flow: modulation of leukocyte-endothelial cell interactions. Am J 
Physiol Heart Circ Physiol 289:H908-915. 
108. Karin M. 2009. NF-kappaB as a critical link between inflammation and cancer. Cold 
Spring Harb Perspect Biol 1:a000141. 
109. Hillman GG, Singh-Gupta V. 2011. Soy isoflavones sensitize cancer cells to 
radiotherapy. Free Radic Biol Med 51:289-298. 
112 
  
 
110. Chun OK, Chung SJ, Song WO. 2007. Estimated dietary flavonoid intake and major 
food sources of U.S. adults. J Nutr 137:1244-1252. 
111. de Kleijn MJ, van der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee 
DE, Jacques PF. 2001. Intake of dietary phytoestrogens is low in postmenopausal 
women in the United States: the Framingham study(1-4). J Nutr 131:1826-1832. 
112. Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA. 2007. Intakes 
and sources of soya foods and isoflavones in a UK population cohort study (EPIC-
Norfolk). Eur J Clin Nutr 61:248-254. 
113. Kim J, Kwon C. 2001. Estimated dietary isoflavone intake of Korean population based 
on National Nutrition Survey. Nutr Res 21:947-953. 
114. Lee SA, Wen W, Xiang YB, Barnes S, Liu D, Cai Q, Zheng W, Shu XO. 2007. 
Assessment of dietary isoflavone intake among middle-aged Chinese men. J Nutr 
137:1011-1016. 
115. Liu Z, Li W, Sun J, Liu C, Zeng Q, Huang J, Yu B, Huo J. 2004. Intake of soy foods 
and soy isoflavones by rural adult women in China. Asia Pac J Clin Nutr 13:204-209. 
116. Surh J, Kim MJ, Koh E, Kim YK, Kwon H. 2006. Estimated intakes of isoflavones 
and coumestrol in Korean population. Int J Food Sci Nutr 57:325-344. 
117. Marugame T, Katanoda K. 2006. International comparisons of cumulative risk of 
breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin 
Oncol 36:399-400. 
118. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, 
Fukami Y. 1987. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J 
Biol Chem 262:5592-5595. 
113 
  
 
119. Messina M. 2010. Insights gained from 20 years of soy research. J Nutr 140:2289S-
2295S. 
120. Bradbury RB, White DE. 1954. Estrogens and related substances in plants. Vitam Horm 
12:207-233. 
121. Curnow DH. 1954. Oestrogenic activity of subterranean clover. II. The isolation of 
genistein from subterranean clover and methods of quantitative estimation. Biochem J 
58:283-287. 
122. Bennetts HW, Underwood EJ, Shier FL. 1946. A specific breeding problem of sheep 
on subterranean clover pastures in Western Australia. Aust Vet J 22:2-12. 
123. Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada 
M, Ohno Y. 1999. Dietary intake and sources of isoflavones among Japanese. Nutrition 
and cancer 33:139-145. 
124. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. 1998. Effect of soymilk 
consumption on serum estrogen concentrations in premenopausal Japanese women. J 
Natl Cancer Inst 90:1830-1835. 
125. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. 2009. Soy food intake and 
breast cancer survival. Jama 302:2437-2443. 
126. Caan BJ, Natarajan L, Parker B, Gold EB, Thomson C, Newman V, Rock CL, Pu 
M, Al-Delaimy W, Pierce JP. 2011. Soy food consumption and breast cancer prognosis. 
Cancer epidemiology, biomarkers & prevention : a publication of the American 
Association for Cancer Research, cosponsored by the American Society of Preventive 
Oncology 20:854-858. 
114 
  
 
127. Guha N, Kwan ML, Quesenberry CP, Jr., Weltzien EK, Castillo AL, Caan BJ. 2009. 
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the 
Life After Cancer Epidemiology study. Breast cancer research and treatment 118:395-
405. 
128. Boyapati SM, Shu XO, Ruan ZX, Dai Q, Cai Q, Gao YT, Zheng W. 2005. Soyfood 
intake and breast cancer survival: a followup of the Shanghai Breast Cancer Study. Breast 
cancer research and treatment 92:11-17. 
129. Kang X, Zhang Q, Wang S, Huang X, Jin S. 2010. Effect of soy isoflavones on breast 
cancer recurrence and death for patients receiving adjuvant endocrine therapy. CMAJ : 
Canadian Medical Association journal = journal de l'Association medicale canadienne 
182:1857-1862. 
130. Woo HD, Park KS, Ro J, Kim J. 2012. Differential influence of dietary soy intake on 
the risk of breast cancer recurrence related to HER2 status. Nutrition and cancer 64:198-
205. 
131. Zhang YF, Kang HB, Li BL, Zhang RM. 2012. Positive effects of soy isoflavone food 
on survival of breast cancer patients in China. Asian Pacific journal of cancer prevention 
: APJCP 13:479-482. 
132. Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T, Yin P. 2014. Association between soy 
isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-
analysis of epidemiological studies. PloS one 9:e89288. 
133. Messina M, Caan BJ, Abrams DI, Hardy M, Maskarinec G. 2013. It's time for 
clinicians to reconsider their proscription against the use of soyfoods by breast cancer 
patients. Oncology 27:430-437. 
115 
  
 
134. Hillman GG, Singh-Gupta V, Hoogstra DJ, Abernathy L, Rakowski J, Yunker CK, 
Rothstein SE, Sarkar FH, Gadgeel S, Konski AA, Lonardo F, Joiner MC. 2013. 
Differential effect of soy isoflavones in enhancing high intensity radiotherapy and 
protecting lung tissue in a pre-clinical model of lung carcinoma. Radiother Oncol 
109:117-125. 
135. Hillman GG, Singh-Gupta V, Lonardo F, Hoogstra DJ, Abernathy LM, Yunker 
CK, Rothstein SE, Rakowski J, Sarkar FH, Gadgeel S, Konski AA, Joiner MC. 
2013. Radioprotection of lung tissue by soy isoflavones. J Thorac Oncol 8:1356-1364. 
136. Mahmood J, Jelveh S, Zaidi A, Doctrow SR, Hill RP. 2013. Mitigation of radiation-
induced lung injury with EUK-207 and genistein: effects in adolescent rats. Radiat Res 
179:125-134. 
137. Singh-Gupta V, Joiner MC, Runyan L, Yunker CK, Sarkar FH, Miller S, Gadgeel 
SM, Konski AA, Hillman GG. 2011. Soy isoflavones augment radiation effect by 
inhibiting APE1/Ref-1 DNA repair activity in non-small cell lung cancer. J Thorac Oncol 
6:688-698. 
138. Messina M, Kucuk O, Lampe JW. 2006. An overview of the health effects of 
isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. 
J AOAC Int 89:1121-1134. 
139. Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher 
ML, Andic F, Rossi PJ, Kucuk O. 2010. Soy isoflavones in conjunction with radiation 
therapy in patients with prostate cancer. Nutrition and cancer 62:996-1000. 
140. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, 
Marples B, Forman JD, Sarkar FH. 2004. Genistein potentiates inhibition of tumor 
116 
  
 
growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3:1271-
1279. 
141. Hill RP, Zaidi A, Mahmood J, Jelveh S. 2011. Investigations into the role of 
inflammation in normal tissue response to irradiation. Radiother Oncol 101:73-79. 
142. Mehta V. 2005. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung 
cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 
63:5-24. 
143. Gough MJ, Young K, Crittenden M. 2013. The impact of the myeloid response to 
radiation therapy. Clin Dev Immunol 2013:281958. 
144. Gensel JC, Zhang B. 2015. Macrophage activation and its role in repair and pathology 
after spinal cord injury. Brain Res. 
145. Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Muller W, Roers A, Eming SA. 
2010. Differential roles of macrophages in diverse phases of skin repair. J Immunol 
184:3964-3977. 
146. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, 
Lang R, Iredale JP. 2005. Selective depletion of macrophages reveals distinct, opposing 
roles during liver injury and repair. J Clin Invest 115:56-65. 
147. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. 1999. 
Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic 
cells. J Immunol 163:3771-3777. 
148. De Brauwer EI, Jacobs JA, Nieman F, Bruggeman CA, Drent M. 2002. 
Bronchoalveolar lavage fluid differential cell count. How many cells should be counted? 
Anal Quant Cytol Histol 24:337-341. 
117 
  
 
149. Bedoret D, Wallemacq H, Marichal T, Desmet C, Quesada Calvo F, Henry E, 
Closset R, Dewals B, Thielen C, Gustin P, de Leval L, Van Rooijen N, Le Moine A, 
Vanderplasschen A, Cataldo D, Drion PV, Moser M, Lekeux P, Bureau F. 2009. 
Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in 
mice. J Clin Invest 119:3723-3738. 
150. Rose S, Misharin A, Perlman H. 2012. A novel Ly6C/Ly6G-based strategy to analyze 
the mouse splenic myeloid compartment. Cytometry A 81:343-350. 
151. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. 2010. Inhibition 
of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell 
recruitment. Proc Natl Acad Sci U S A 107:8363-8368. 
152. Cappuccini F, Eldh T, Bruder D, Gereke M, Jastrow H, Schulze-Osthoff K, Fischer 
U, Kohler D, Stuschke M, Jendrossek V. 2011. New insights into the molecular 
pathology of radiation-induced pneumopathy. Radiother Oncol 101:86-92. 
153. Chiang CS, Liu WC, Jung SM, Chen FH, Wu CR, McBride WH, Lee CC, Hong JH. 
2005. Compartmental responses after thoracic irradiation of mice: strain differences. Int J 
Radiat Oncol Biol Phys 62:862-871. 
154. Zaynagetdinov R, Sherrill TP, Kendall PL, Segal BH, Weller KP, Tighe RM, 
Blackwell TS. 2013. Identification of myeloid cell subsets in murine lungs using flow 
cytometry. Am J Respir Cell Mol Biol 49:180-189. 
155. Gordon S, Taylor PR. 2005. Monocyte and macrophage heterogeneity. Nat Rev 
Immunol 5:953-964. 
156. Wu G, Morris SM, Jr. 1998. Arginine metabolism: nitric oxide and beyond. Biochem J 
336 ( Pt 1):1-17. 
118 
  
 
157. Laskin DL, Sunil VR, Gardner CR, Laskin JD. 2011. Macrophages and tissue injury: 
agents of defense or destruction? Annu Rev Pharmacol Toxicol 51:267-288. 
158. Zhang H, Han G, Liu H, Chen J, Ji X, Zhou F, Zhou Y, Xie C. 2011. The 
development of classically and alternatively activated macrophages has different effects 
on the varied stages of radiation-induced pulmonary injury in mice. J Radiat Res 52:717-
726. 
159. Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73:209-
212. 
160. Gordon S, Martinez FO. 2010. Alternative activation of macrophages: mechanism and 
functions. Immunity 32:593-604. 
161. Morris SM, Jr. 2007. Arginine metabolism: boundaries of our knowledge. J Nutr 
137:1602S-1609S. 
162. Ao X, Zhao L, Davis MA, Lubman DM, Lawrence TS, Kong FM. 2009. Radiation 
produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and 
resistant mice. J Hematol Oncol 2:6. 
163. Wang XP, Chen YG, Qin WD, Zhang W, Wei SJ, Wang J, Liu FQ, Gong L, An FS, 
Zhang Y, Chen ZY, Zhang MX. 2011. Arginase I attenuates inflammatory cytokine 
secretion induced by lipopolysaccharide in vascular smooth muscle cells. Arterioscler 
Thromb Vasc Biol 31:1853-1860. 
164. Droke EA, Hager KA, Lerner MR, Lightfoot SA, Stoecker BJ, Brackett DJ, Smith 
BJ. 2007. Soy isoflavones avert chronic inflammation-induced bone loss and vascular 
disease. J Inflamm (Lond) 4:17. 
119 
  
 
165. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, 
Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. 2007. PPARgamma 
activation primes human monocytes into alternative M2 macrophages with anti-
inflammatory properties. Cell Metab 6:137-143. 
166. Wang N, Liang H, Zen K. 2014. Molecular mechanisms that influence the macrophage 
m1-m2 polarization balance. Frontiers in immunology 5:614. 
167. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, 
Sarkar FH, Hillman GG. 2007. Down-regulation of apurinic/apyrimidinic endonuclease 
1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in 
vitro and in vivo. Cancer research 67:2141-2149. 
168. Martin M, Lefaix J, Delanian S. 2000. TGF-beta1 and radiation fibrosis: a master 
switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 47:277-290. 
169. Leask A, Abraham DJ. 2004. TGF-beta signaling and the fibrotic response. FASEB J 
18:816-827. 
170. Santak G, Santak M, Forcic D. 2010. The role of interleukin-1beta and platelet-derived 
growth factor-AB in antifibrosis mediated by native human interferon alpha. Surgery 
148:490-498. 
171. Lemberger T, Desvergne B, Wahli W. 1996. Peroxisome proliferator-activated 
receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev 
Biol 12:335-363. 
172. Hart CM, Roman J, Reddy R, Sime PJ. 2008. PPARgamma: a novel molecular target 
in lung disease. J Investig Med 56:515-517. 
120 
  
 
173. Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. 2007. 
The Role of PPARs in Lung Fibrosis. PPAR Res 2007:71323. 
174. Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. 2005. Molecular mechanisms 
of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A 
review. J Nutr Biochem 16:321-330. 
175. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. 2003. Peroxisome 
proliferator-activated receptors: regulation of transcriptional activities and roles in 
inflammation. J Steroid Biochem Mol Biol 85:267-273. 
176. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos 
J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, 
Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. 2010. Meta-analysis of 
concomitant versus sequential radiochemotherapy in locally advanced non-small-cell 
lung cancer. J Clin Oncol 28:2181-2190. 
177. Guida C, Maione P, Rossi A, Bareschino M, Schettino C, Barzaghi D, Elmo M, 
Gridelli C. 2008. Combined chemo-radiotherapy for locally advanced non-small cell 
lung cancer: current status and future development. Crit Rev Oncol Hematol 68:222-232. 
178. Lo SS, Sahgal A, Chang EL, Mayr NA, Teh BS, Huang Z, Schefter TE, Yao M, 
Machtay M, Slotman BJ, Timmerman RD. 2013. Serious complications associated 
with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol (R 
Coll Radiol) 25:378-387. 
179. Soliman H, Cheung P, Yeung L, Poon I, Balogh J, Barbera L, Spayne J, Danjoux C, 
Dahele M, Ung Y. 2011. Accelerated hypofractionated radiotherapy for early-stage non-
small-cell lung cancer: long-term results. Int J Radiat Oncol Biol Phys 79:459-465. 
121 
  
 
180. Videtic GM, Stephans KL. 2010. The role of stereotactic body radiotherapy in the 
management of non-small cell lung cancer: an emerging standard for the medically 
inoperable patient? Curr Oncol Rep 12:235-241. 
  
122 
  
 
ABSTRACT 
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Radiation-induced lung injury (RILI) is caused by an early inflammatory process 
triggered by damage to lung parenchyma, epithelial cells, vascular endothelial cells and stroma. 
Initially, oxidative injuries after radiation induce altered expression of pro-inflammatory 
cytokines. Infiltrating inflammatory cells are stimulated and activated, producing additional 
mediators, resulting in a cytokine cascade. The expansion and perpetual activation of 
inflammatory cells, as well as lung parenchyma, lead to clinical pneumonitis. Activated cells 
produce molecular mediators and growth factors that affect the proliferation and gene expression 
of lung fibroblasts. This process leads to increased collagen synthesis and deposition, eventually 
leading to the development of lung fibrosis. These adverse events after radiotherapy affect 
patients’ breathing and their quality of life. Various strategies to decrease the extent of 
pneumonitis have been investigated but need further research efforts. 
We have previously demonstrated in mice receiving a single high dose of thoracic 
irradiation that supplementation with a mixture soy isoflavones (genistein, daidzein, and 
glycitein) has the dual capability of protecting normal lung tissue from radiation injury while 
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simultaneously enhancing radiation damage in the tumor. However, mechanisms of 
radioprotection by soy isoflavones in normal tissues remained to be elucidated. We hypothesized 
that soy isoflavones mediate radioprotection via the modulation of radiation-induced 
inflammatory processes involving macrophages, neutrophils, and myeloid-derived suppressor 
cells.  
The major findings of this work suggest that soy isoflavones can inhibit inflammatory 
responses triggered by a single dose of thoracic irradiation in the lung, including NF-κB and pro-
inflammatory cytokine production. We reveal that soy isoflavones inhibit the infiltration and 
activation of macrophages and neutrophils in the lung induced by radiation. Radiation induced a 
pro-inflammatory M1 macrophage phenotype in lungs, while mice receiving soy isoflavones and 
radiation switched to an anti-inflammatory M2 macrophage subtype. Soy isoflavones had a 
protective effect on regulatory interstitial macrophages (IM) after irradiation, while inhibiting 
alveolar macrophage (AM) infiltration and activation induced by radiation. Interestingly, we 
show that soy isoflavones promote granulocytic myeloid-derived suppressor cells that express 
Arg-1 after radiation, resulting in subsequent downregulation inflammatory mediators. These 
data indicate that lung radioprotection by soy isoflavones may occur via the modulation of 
cellular and molecular mediators involved in the inflammatory response induced by radiation. 
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